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ABSTRACT  
The aim of this thesis was to examine the cell signaling and regulation of smooth muscle in 
different smooth muscle tissues and under pathophysiological conditions. The thesis is based 
on 4 papers and the experimental work is based on in vitro studies in mouse.  
In Paper I we addressed the question if key characteristics of fast and slow smooth muscle 
types could be identified, based on contractile, cell signaling and metabolic properties. We 
examined 4 different smooth muscle mouse tissues (aorta, muscular arteries, intestine, urinary 
bladder) with a large span in contractile kinetics (Vmax, maximal shortening velocity) based 
on SM-B expression (”fast” inserted myosin heavy chain). A quantitative PCR (qPCR) and 
Western blot approach was used to examine expression of key components in the contractile, 
metabolic and cell signaling pathways. A large variability between different smooth muscle 
tissues was found regarding contractile, cell signaling and metabolism. The reported main 
characteristics of fast and slow smooth muscle can serve as a basis for future studies of 
smooth muscle properties.     
In Paper II we addressed the question if the two main Ca2+-sensitizing pathways: RhoA-
Rhokinase and protein kinase C (PKC) are altered in response to hypertrophic growth in the 
urinary bladder. We used a mouse model, partial urinary outlet obstruction, to induce 
hypertrophic growth of the smooth muscle. It mimics the over active bladder syndrome 
(OAB) in man, a pathophysiological condition affecting the urinary bladder with sudden and 
frequent urges to urinate, nocturia and urge incontinence. To examine if active force was 
altered, we used in vitro force recordings and direct nerve stimulation in open organ baths. 
Western blot analysis was used to determine if the relative protein expression of components 
mediating signaling in the RhoA-Rhokinase and PKC pathways. Direct nerve stimulation 
showed an increased cholinergic response in the hypertrophic smooth muscle, with a lower 
purinergic and increased nerve independent component. The hypertrophic smooth muscle 
also had an increased sensitivity to cholinergic stimulation and increased Rho dependent Ca2+ 
sensitivity that correlated with a lower phosphatase (MYPT1) expression and higher 
expression of both RhoGDI and RhoA. Based on these results and the profiling of the cell 
signaling in Paper I, it seems likely that hypertrophic growth of the urinary bladder induces 
transition from a fast smooth muscle type towards a slow smooth muscle type.  
In Paper III we addressed the question if nonmuscle myosin (NMM) can be upregulated in 
response to hypertrophic growth in the urinary bladder and be involved in a PKC-induced 
contractile component observed in the hypertrophying urinary bladder. We examined the 
relative expression of NMM with Western blot and immunohistochemistry. Active force was 
analyzed using in vitro force recordings in open organ baths. In addition to smooth muscle 
myosin (SMM), the smooth muscle can express NMM, able to support a contraction with 
slow kinetics. However, in the urinary bladder NMM is only expressed during fetal life and 
downregulated shortly after birth. Western blot analysis showed an increased NMM 
expression in the hypertrophic smooth muscle compared to control. Immunohistochemistry 
showed an increased expression of NMM in the suburothelium, the smooth muscle layer and 
the serosa, for the hypertrophic urinary bladder compared to the control bladder. Direct 
activation of protein kinase C (PKC) with PDBu gave a prominent contraction that was 
independent of Rhokinase. Blebbistatin is an inhibitor of nonmuscle myosin, with higher 
affinity for NMM than for SMM. The PKC induced contraction was almost completely 
abolished by blebbistatin, indicating that NMM is involved in this unique contractile 
component in hypertrophic urinary bladder. Smooth muscle from the hypertrophying urinary 
bladder can thus develop a unique PKC activated contractile component based on nonmuscle 
myosin, mainly localized to the serosa. However, this contractile component is not a major 
part of the normal muscarinic contraction, instead it may contribute to wall stiffness and be 
activated by other (unknown) upstream pathways.  
In Paper IV we addressed the question if smooth muscle contraction is sensitive to metabolic 
inhibition and if there is a difference in sensitivity to metabolic block between fast and slow 
smooth muscle types, due to their different metabolic properties determined in Paper I.  The 
mechanisms of metabolic control of smooth muscle are poorly understood. We approached 
this question by introducing a partial metabolic blocker (rotenone) of complex I in the 
mitochondria, resembling e.g. ischemic conditions due to atherosclerotic changes or ageing. 
To confirm that rotenone slows down the mitochondrial respiration, we measured oxygen 
consumption in the relaxed smooth muscle tissue and found about 50% inhibition by 
rotenone. We measured active force using in vitro force recordings in open organ bath, in the 
presence of blockers and activators to target membrane channels and cellular component that 
potentially might be affected by the metabolic stress induced by rotenone. Active force of the 
fast (urinary bladder) was more sensitive to rotenone than that of the slow smooth muscle 
(aorta), which correlates well with the metabolic profiling in Paper I. AMP-kinase, a 
metabolic sensor, is activated by metabolic stress (increased ADP:ATP and/or AMP:ATP 
ratios) and initiates a range of energy-saving processes in the cell. AICAR (AMPK activator) 
partially attenuated the rotenone effects on contraction, whereas dorsomorphin (AMPK 
blocker) dramatically increases the inhibitory effect of rotenone. Thus, AMPkinase appears to 
have a protective action during metabolic stress induced by rotenone in the smooth muscle. 
In summary, this thesis demonstrates a large variability between fast and slow smooth muscle 
tissues regarding contractile properties, signaling and metabolism. Smooth muscle has an 
impressive ability to adapt during pathophysiological stress, e.g. in the urinary bladder. In the 
hypertrophic bladder muscle cell signaling is affected, increasing both the nerve induced 
cholinergic component and Rho-mediated Ca2+ sensitivity. In addition, hypertrophic smooth 
muscle can also develop a unique contractile component dependent on nonmuscle myosin 
that is activated by PKC. Partial metabolic block inhibits active force in the smooth muscle 
and can partially be prevented by AMPkinase. Compared to the slow smooth muscle, the fast 
smooth muscle is more sensitive to metabolic stress induced by rotenone. 
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LIST OF ABBREVIATIONS 
ACC2 acetyl-Coenzyme A carboxylase beta                                  
ACh acetylcholine 
ADP adenosine diphosphate 
AMPK AMP-activated protein kinase 
ATP adenosine triphosphate 
BKCa channel big conductance Ca2+-activated K+ channel 
CCh carbachol 
CPI17 small signaling protein, activated CPI17 is a very powerful 
inhibitor of the MLCP catalytic subunit, PP1c 
DAG diacylglycerol 
FAS fatty acid synthase 
GAP GTPase activating protein 
GDI GDP dissociation inhibitor 
GDP guanosine diphosphate 
GEF guanine nucleotide exchange factor 
GPCR G-protein coupled receptor 
GTP guanosine-5'-triphosphate 
Gαq isoform of G-protein coupled receptor, activates both the 
PKC and the Rho-Rho-kinase pathway 
Gα12/13 isoform of G-protein coupled receptor, activates the Rho-
Rho-kinase pathway 
G6P glucose-6-phosphate, metabolite formed in the first step of 
glycolysis 
G6PDH glucose-6-phosphate dehydrogenase, enzyme in the pentose 
phosphate pathway 
GLUT1 insulin-independent glucose transporter, facilitate transport of 
glucose over a plasma membrane independent of insulin 
GLUT4 insulin-dependent glucose transporter, facilitate an insulin-
regulated transport of glucose over a plasma membrane. 
HEXO hexokinase, regulatory enzyme in glycolysis  
HPRT hypoxanthine guanine phosphoribosyl transferase, 
housekeeping gene 
  
HSL hormone sensitive lipase 
IP3 inositol-trisphosphate 
IP3R IP3-receptor facilitates release of Ca2+ from SR 
KATP ATP sensitive potassium channel activated by low 
intracellular ATP concentration, and hyperpolarizes the 
plasma membrane. 
LC20 myosin regulatory light chain 
LDH lactate dehydrogenase, enzyme facilitating lactate formation 
LPL lipoprotein lipase 
LC17a, LC17b acidic and basic splice variant of myosin essential light chain 
L-type Ca2+ channel long-lasting (activating) voltage-gated calcium channel 
LUTS lower urinary tract symptoms 
MLCK myosin light chain kinase, phosphorylates and induces 
smooth muscle contraction  
MLCP myosin light chain phosphatase, dephosphorylates and 
induces smooth muscle relaxation  
MCD malonyl-CoA decarboxylase 
MYPT1 myosin phosphatase regulatory targeting subunit, a subunit of 
MLCP 
NADH reduced nicotinamide adenine dinucleotide 
NADPH reduced nicotinamide adenine dinucleotide phosphate 
NMM nonmuscle myosin  
NO nitric oxide 
OAB over active bladder syndrome 
PCR polymerase chain reaction 
PEP phosphoenolpyruvate, a metabolite in glycolysis 
PEPCK phosphoenolpyruvate carboxykinase 
PIP2 phosphatidylinositol bisphosphat 
PKA cAMP-dependent kinase 
PKC protein kinase C 
PKG cGMP-dependent kinase 
PLC phospholipase C 
PP1c catalytic subunit of MLCP 
PYRK pyruvate kinase 
qPCR real-time polymerase chain reaction 
ROCK Rho-associated protein kinase. 
RhoA Ras homolog gene family member A, small GTPase protein 
SKCa channel small conductance Ca2+-activated K+ channel 
SM1 isoform smooth muscle heavy chain, unique sequence of 43 
amino acids (~204 kDa) in C-terminal comprising a kinase 
phosphorylation site, SM2 is the shorter form 
SM-B “fast myosin”, isoform of smooth muscle heavy chain with 9 
amino acid insert in the N-terminal close to its ATPase site 
that creates a myosin construct that pushes the actin at a 
higher velocity. SM-A is the form lacking the insert. 
SR sarcoplasmic reticulum, an intracellular Ca2+ store of the 
smooth muscle 
TFAM mitochondrial transcription factor A 
 
  1 
1 INTRODUCTION 
 
1.1 THE CONTRACTILE MACHINERY OF SMOOTH MUSCLE 
Smooth muscle is a heterogenic tissue that plays an important role in many elementary 
physiological processes in the body, i.e. in the vascular system, the airways, the 
gastrointestinal tract, the urinary bladder and the uterus, as presented in many textbooks of 
physiology (e.g. Boron and Boulpaep, 2005).  
All muscle types generate force and shortening via actin-myosin interaction, a process 
regulated by variations in intracellular [Ca2+] (Cooke, 1997). Myosin is a highly conserved 
ATP-dependent motor protein that is responsible for the actin-based motility. Smooth muscle 
contraction is due to a cyclic interaction of myosin cross-bridges with actin, in a similar 
manner as in the striated and cardiac muscles (Andersson and Arner, 2004). In this process, 
myosin converts chemical energy into mechanical work associated with the ATP hydrolysis 
reaction. This is a multistep enzymatic process where MgATP is hydrolyzed to MgADP and 
Phosphate (Pi). Smooth muscle contraction is dependent on constant energy flow from the 
cell metabolism, keeping the MgATP at high levels and removing MgADP and Pi. In 
comparison to striated muscles the smooth muscle ATP and cross-bridge turnover rates are 
50-100 times slower, as reflected by a low ATPase and a low shortening velocity (Bárány, 
1967), but a high economy while keeping force (e.g. Paul, 1980). The rate of cross-bridge 
dissociation during cycling is associated with ADP release and this enzymatic step is 
considerable slower in smooth compared to striated muscles (Löfgren et al., 2001), explaining 
the slow shortening velocity and high tension economy (i.e. maintenance of force related to 
ATPase). It should be noted that there is a large span in cross-bridge turnover between 
different smooth muscle types (Malmqvist and Arner, 1991), where the aorta and urinary 
bladder represent comparatively slow and fast smooth muscle types, respectively, as 
discussed below (section 1.5).     
 
1.2 ISOFORMS OF CONTRACTILE PROTEINS 
The expression of the smooth muscle contractile proteins actin and myosin, involves different 
protein isoforms. Actin is a highly conserved protein that exhibits a considerable degree of 
homology between different isoforms. In smooth muscle four actin isoforms (α-, β-, and a 
smooth and nonmuscle variant of γ-actin) are expressed (cf. Drew and Murphy, 1997). Their 
functional characteristics are not yet fully understood, but the isoforms appear to have similar 
effects on cross-bridge turnover (Harris and Warsaw, 1993; Drew and Murphy, 1997). The 
actin isoform expression is thus not primarily responsible for the slow kinetics of smooth 
muscle or the difference between fast and slow smooth muscle types. Myosin in smooth 
muscle belongs to the filament forming myosin II superfamily (Walklate et al., 2016). The 
myosin molecule is a complex of six polypeptide chains arranged as a hexamer; containing 
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the two heavy chains (with the ATPase and actin binding sites), two regulatory light chains 
(20 kDa) and two essential light chains (17 kDa). Different isoforms of smooth muscle heavy 
chain are generated through alternative splicing in the COOH- (SM1 and SM2) and the NH2-
terminal (SM-A and SM-B, cf. Andersson and Arner, 2004). The SM1 and SM2 have unique 
sequences in the filament forming region, comprising a kinase phosphorylation site in SM1. 
In the urinary bladder the ratio SM1/SM2 is lower in adult tissue, possibly suggesting 
differential role of these isoforms in development. However, the SM1 and SM2 isoforms do 
not have a major role in controlling the contractile kinetics (cf. Andersson and Arner, 2004). 
On the other hand, the isoforms in the NH2-terminal region (SM-A and SM-B) are close to 
the ATPase site of myosin. The SM-B myosin translocates actin at a higher velocity. Thus, 
the expression of the inserted SM-B smooth muscle myosin is considered a major regulator of 
smooth muscle kinetics (Kelley et al., 1993).  
Also, the myosin essential light chains are expressed in two variants in smooth muscle 
through alternative splicing, the acidic (LC17a) and the basic nonmuscle (LC17b). Both a low 
shortening velocity and low ATPase activity are correlated with the LC17b isoform (cf. Arner 
et al., 2003). It is thus most likely a combination between different isoforms of smooth 
muscle heavy chain (SM-A and SM-B) and smooth muscle essential light chains (LC17a and 
LC17b) that determines, or at least correlates strongly with, the contractile kinetics in different 
smooth muscle types, a fast smooth muscle has higher expression of SM-B and of LC17a. 
Besides the smooth muscle myosin II discussed above, filament forming nonmuscle myosin 
II can also be expressed in smooth muscle and support contraction (Morano et al., 2000). 
Two isoforms, encoded by separate genes, give rise to nonmuscle myosin heavy chain A 
(NM-MHC-A) and B (NM-MHC-B). NM-MHC-B is expressed in embryonic and newborn 
urinary bladders, and most likely critical for normal development. It can also be found in 
nonmuscle cells.  Smooth muscles with high amounts of nonmuscle myosins have slow 
cross-bridge kinetics (Löfgren et al., 2003; Rhee et al., 2006). 
 
1.3 ACTIVATION AND DEACTIVATION OF SMOOTH MUSCLE CONTRACTION 
Activation of smooth muscle contraction is initiated by an increase in the cytosolic calcium 
level [Ca2+]i, either by Ca2+ influx from the extracellular space or by Ca2+ release from 
intracellular stores (i.e. sarcoplasmatic reticulum, SR).  
Voltage gated L-type Ca2+ channels are a main source of Ca2+ influx and their activity are 
triggered by depolarization or receptor activation (Jaggar el al., 1998). Since they are 
dependent on membrane potential, K+ channels have important roles in regulating the L-type 
Ca2+ channel opening probability. Opening of small conductance (SK) and large conductance 
(BK) K+ channels, due to Ca2+ increase (Jaggar el al., 1998; Herrera and Nelson, 2002) or of 
ATP dependent KATP channels by low ATP (Tinker et al., 2014) will hyperpolarize the 
membrane and induce relaxation.  
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Free cytosolic Ca2+ binds to calmodulin and activates the Ca2+-calmodulin-dependent myosin 
light chain kinase (MLCK). MLCK is ubiquitously expressed in several muscle tissues and it 
phosphorylates the Ser-19 of the smooth myosin regulatory light chain (LC20) and thereby 
allowing the cross-bridge cycle between myosin heads and actin to start (Horowitz et al., 
1996; Somlyo and Somlyo, 2003). For the smooth muscle to relax, dephosphorylation of the 
LC20 by myosin light chain phosphatase (MLCP) is required. MLCP is a heterotrimeric 
protein that consists of a catalytic subunit (PP1c), myosin phosphatase regulatory targeting 
subunit (MYPT1) and a 20 kDa subunit of unidentified function (Somlyo and Somlyo, 2003; 
Andersson and Arner, 2004). MYPT1 affects the catalytic activity of MLCP and its activity is 
regulated by phosphorylation by several different kinases. In addition, the MLCP activity can 
be modulated by binding of CPI17; when phosphorylated, mainly by protein kinase C (PKC), 
it inhibits the phosphatase (Woodsome et al., 2001). 
 
 
1.4 Ca2+-SENSITIVITY MODULATION OF SMOOTH MUSCLE CONTRACTION 
The main activation/deactivation pathway of smooth muscle is the Ca2+ activation of the 
MLCK and the dephosphorylation by the MLCP (section 1.3, Figure 1). An important aspect 
of this regulation is that the “Ca2+-sensitivity” can be regulated, i.e. at a given intracellular 
concentration of Ca2+ the amount of force developed can vary depending on the type of 
excitatory stimulus (cf. Rembold, 1992; Arner and Pfitzer, 1999; Somlyo and Somlyo, 2003). 
The Ca2+ sensitivity and extent of myosin light chain phosphorylation in smooth muscle are 
generally considered to be determined by the ratio between activated MLCK and activated 
MLCP. Agonist-induced activation of the smooth muscle can cause a shift in this balance in 
favor of the MLCK. Although MLCK activity can be modulated by cellular signaling, MLCP 
appears to be a key target for this Ca2+-sensitivity modulation in smooth muscle. When 
MLCP is less active, dephosphorylation is inhibited and consequently the smooth muscle can 
be phosphorylated and contract at a lower [Ca2+]i (Somlyo and Somlyo, 2003). 
Protein kinase C (PKC) and Rho-kinase (ROCK) are the two main cellular pathways that 
terminate on the MLCP and inhibit its activity, which leads to an increased Ca2+ sensitivity of 
smooth muscle (Somlyo and Somlyo, 2003). These Ca2+-sensitizing pathways are illustrated 
Figure 1. Illustration of activation and 
deactivation of smooth muscle contraction. 
Calcium (Ca2+) binds to calmodulin (CaM) and 
activates myosin light chain kinase (MLCK), 
which phosphorylates the regulatory light 
chains (LC20) and activates contraction. Smooth 
muscle relaxation requires dephosphorylation 
of the regulatory light chains by myosin light 
chain phosphatase (MLCP), consisting of three 
subunits PP1c, MYPT1 and a 20kDa subunit. 
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schematically in Figure 2. The PKC and Rho-kinase pathways can be recruited either after 
ligand binding to G-protein coupled receptors in the plasma membrane or directly by an 
increase in intracellular [Ca2+]. Force induced by the binding of various agonists to a G-
protein coupled receptor (GPCR) is generally higher compared to force induced by 
depolarization (high K+) of the plasma membrane, due to the Ca2+ sensitization associated 
with agonist binding to cellular receptors (Rembold, 1990). Depending on the GPCR isoform 
stimulated, different Ca2+-sensitizing pathways can be recruited, i.e. most Gαq activate both 
the PKC and the Rho-Rho-kinase pathway whereas Gα12/13 mainly recruit the Rho-Rho-kinase 
pathway (Somlyo and Somlyo, 2003).  In the resting smooth muscle cell, cytoplasmic RhoA-
GDP is complexed with GDI (GDP dissociation inhibitor), thus promoting a deactivated Rho-
pathway. Trimeric G-proteins are coupled to GEFs (guanine nucleotide exchange factors) and 
agonist binding to GPCR activates GEFs. GEFs activate the RhoA by catalyzing the 
exchange of nucleotide bound to RhoA, from GDP to GTP. Activated RhoA-GTP 
translocates to the plasma membrane and subsequently activates Rhokinase (ROCK). RhoA 
is returned to the inactivated GDP-bound from a process stimulated by GAP (GTPase-
activating protein). ROCK is considered to phosphorylate a tyrosine residue on the myosin 
binding subunit (MYPT1) of MLCP and thereby inhibit phosphatase activity and increase the 
force development (Somlyo and Somlyo, 2003). 
 
Figure 2. Main Ca2+ sensitizing pathways for activation of smooth muscle contraction. 
Depolarization of the plasma membrane opens L-type Ca2+ channels, leading to Ca2+ influx. Receptor 
activation can cause depolarization, but also generate inositol trisphosphate (IP3) leading to 
sarcoplasmic reticulum (SR) Ca2+ release and to diacylglycerol (DAG) activation of protein kinase C 
(PKC). It also leads to activation of RhoA and Rhokinase (ROCK). Whereas Ca2+ activates the 
Myosin Light Chain Kinase (MLCK), both PKC (via CPI17) and ROCK inhibit the Myosin Light 
Chain Phosphatase (MLCP) and increase the Ca2+-sensitivity. 
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Protein kinase C (PKC) can be activated by diacylglycerol (DAG) generated by 
phospholipase C and some isoforms also by Ca2+ (Morgan and Leinweber, 1998; Somlyo and 
Somlyo, 2003; Ringvold and Khalil, 2017). Receptor activation of phospholipase C (PLC) 
results in hydrolysis of PIP2 (phosphatidylinositol-bisphosphate) into IP3 (inositol-
trisphosphate) and DAG (diacylglycerol). IP3 binds to a receptor in the SR (IP3R) which 
results in Ca2+ release. DAG activates protein kinase C (PKC) which in turn activates several 
pathways including its key substrate CPI17 via phosphorylation. Phosphorylated CPI17 is a 
powerful inhibitor of the MLCP catalytic subunit, PP1c (Woodsome et al., 2001). 
In many ways, smooth muscle tone is modulated in vivo by both regulation of activation, as 
described above, and by activation of relaxation, e.g. in vascular and in erectile tissues. Nitric 
oxide (NO), released from endothelium, and specific receptor-stimulation are important 
relaxant mechanisms which directly, or via cGMP/PKG or cAMP/PKA, affect several 
pathways leading to lowering of intracellular Ca2+-levels and the decreased Ca2+-sensitivity 
(Morgado et al., 2012).   
 
1.5 VARIABILITY BETWEEN DIFFERENT SMOOTH MUSCLE TISSUE TYPES 
Smooth and striated (skeletal and cardiac) muscle is generally divided into different types 
according to their histological appearance (e.g. Boron and Boulpaep, 2005). The smooth 
muscle is however a heterogeneous group and displays a large variability in contractile, 
regulatory and electrophysiological characteristics. Different smooth muscle tissues also 
manifest great variation in their sensitivity to hormones, neurotransmitters, physical/chemical 
factors and pharmacological compounds. Agonist stimulation/binding can give different 
responses depending on the receptor expression and type of smooth muscle tissue, which 
allows for a remarkable adaptation of the muscle function to the physiological demands in the 
specific organ system. 
Smooth muscle is regulated by the autonomic nervous system and exhibits a more diverse 
innervation and intercellular communication compared to skeletal and cardiac muscle. Emil 
Bozler (Bozler, 1948) proposed a model dividing smooth muscle into two discrete groups 
based on the innervation and electrical coupling: single unit (visceral) and multiunit. In the 
latter group, each smooth muscle cell receives input from neurons and there is little electrical 
coupling between the individual smooth muscle cells. Thus, the multiunit (e.g. in the ocular 
smooth muscle) allows better control/modification since smooth muscle cells can contract 
independently of each other. In contrast, single unit smooth muscle can contract coordinated 
as a unit, since it has extensive electrical coupling with only a few smooth muscle cells 
receiving neural input and can be spontaneously active (e.g. smooth muscle in the gut). This 
view can be found in many physiological textbooks. Nevertheless, Bozler´s model does not 
entirely explain the diversity of smooth muscle, since the innervation and electrical coupling 
of different smooth muscle tissues display a continuum of these characteristic rather than 
being discrete groups. The group of Somlyo and Somlyo proposed that smooth muscle should 
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be divided into “phasic” and “tonic” types (Somlyo et al., 1969), based on membrane 
properties and the contractile behavior exhibited after agonist activation. The phasic smooth 
muscles have a fast and transient force development compared to the tonic that exhibit a slow 
and sustained contraction. It has also been recognized that the “phasic” and “tonic” types 
differ in their excitation pathways, e.g. in the phosphatase activity, and several other 
parameters of the contractile system (Fisher, 2010).  
It is interesting to note that smooth muscle exhibits a large span (5-7 fold) in contractile 
kinetics (as measured by the maximal shortening velocity), where slow smooth muscles (e.g. 
in the aorta) and fast smooth muscle (e.g. visceral smooth muscles) can be identified (Arner 
et al., 2003). The shortening velocity reflects the kinetics of the actin-myosin cross-bridge 
turnover, most likely the rate of ADP release, and has been correlated with the myosin 
isoform expression (section 1.1). As discussed above, phasic (similar to fast) and tonic 
(similar to slow) smooth muscles differ in cellular signaling for contractile 
activation/deactivation (Fisher, 2010).  
It seems also likely that the contractile turnover and the ADP sensitivity are correlated with 
properties in the metabolic pathways. An interesting approach for further characterization or 
classification of smooth muscle types could be to simultaneously consider the contractile, 
metabolic and signaling properties. This might enable a better understanding of the smooth 
muscle diversity, although such an approach has not been explored previously. It is well 
known that the smooth muscle has a low ATP turnover, and is thus generally considered an 
“economical” muscle. However, a more detailed analysis of the variability in energy 
metabolism between smooth muscle types is missing. 
  
1.6 GENERAL FUNCTION OF KEY ENZYMES IN THE METABOLIC 
PATHWAYS 
The constant energy flow from ingested nutrients containing proteins, carbohydrates and 
lipids is vital to uphold key processes in cellular function. The nutrients are metabolized in 
several steps to yield ATP (adenosine triphosphate), which is the universal chemical energy 
carrier in the cell. In the smooth muscle, the chemical energy is mainly transformed to 
mechanical work although activation/deactivation processes also are ATP dependent (e.g. 
Ca2+ translocation, myosin phosphorylation, ATP dependent membrane processes etc.).  
Below a simplified overview of the general metabolic pathways involved in ATP generation 
in muscle are presented, focusing of key steps analyzed in Paper I of this thesis. A full 
account of all metabolic steps is not presented, but rather some key reactions used in the 
metabolic “profiling” of smooth muscle types. An overview is given below (cf. Alberts et al., 
1989; Lehninger et al., 2000). 
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1.6.1 Glucose uptake and glycolysis  
The mammalian plasma membrane contains a lipid bilayer that is impermeable to glucose, 
which thus requires specific membrane transporter to enter the cell. GLUT proteins, a family 
of integral membrane glycoproteins, facilitates transport of glucose across the plasma 
membrane. GLUT 1 and GLUT4 are expressed in (vascular) smooth muscle cells (Ebeling, 
1998). GLUT1 facilitates transport of glucose over a plasma membrane independent of 
insulin and assures a low level of basal glucose uptake required to sustain respiration in all 
cells (Ebeling, 1998).  
GLUT4 is extensively expressed in adipose tissues and striated muscle. GLUT4 facilitate an 
insulin-regulated transport of glucose over the plasma membrane (Ebeling, 1998; Park, et al., 
2005). To meet increased energy demand during muscle contraction, insulin induces 
translocation and fusing of GLUT4 vesicles to the plasma membrane, facilitating a rapid 
increase in the uptake of glucose (Park et al., 2005; Belman et al., 2014). 
 
 
 
Glycolysis (Fig. 3) is a highly regulated and oxygen independent catabolic pathway that 
converts glucose into pyruvate via ten steps of enzyme-catalyzed reactions, generating ATP 
and NADH (reduced nicotinamide adenine dinucleotide). In the first step of glycolysis, 
hexokinase converts glucose to Glucose 6-phosphate (G6P) at the expense of one ATP, a 
rate-limited and irreversible step (Roberts and Miyamoto, 2015). The final step of glycolysis 
is also irreversible and rate-limited in the catabolic pathway, pyruvate kinase (PYRK) 
catalyzes the transfer of a phosphate group from phosphoenolpyruvate (PEP) to adenosine 
diphosphate (ADP), resulting in the generation of ATP and pyruvate. Depending on the 
Figure 3. Simplified schematic 
of glycolysis. Glucose enters the 
cell and is broken down to 
pyruvate, via several irreversible 
and rate-limited steps. Hexokinase 
and pyruvate kinase controls the 
first and last of these steps, 
respectively. Depending on 
oxygen access and metabolic state 
of the cell, synthesized pyruvate 
can take different routes: aerobic 
as acetyl-CoA and enter Krebs 
cycle, or anaerobic and be 
converted to lactate by lactate 
dehydrogenase. 
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metabolic state of the muscle and access to oxygen, pyruvate can either enter the Krebs cycle 
or be reduced to lactate, when aerobic or anaerobic condition is in favor respectively.   
1.6.2 The lactate production  
Krebs cycle is an oxygen-dependent pathway where ATP is generated from acetyl-CoA via a 
chain of enzyme-catalyzed reactions and the main source for ATP production in the cell.  
However, during anaerobic conditions lactate dehydrogenase (LDH) converts pyruvate and 
NADH to lactate and NAD+ to meet the energy demand of the cell (Fig. 3). This enzymatic 
reaction is completely reversible and is regulated by feed-back inhibition, when lactate 
concentration is high. Interestingly, in the slow smooth muscle high amount of lactate is 
produced also during aerobic conditions (Paul, 1980). The underlying cause/function for this 
phenomenon has not been determined and different mechanisms have been proposed e.g. 
higher expression of hexokinase (Roberts and Miyamoto 2015) and glycolytic driven Na/K 
ATPase in the plasma membrane (Lynch and Paul 1983). 
1.6.3  The gluconeogenesis  
Gluconeogenesis (Fig. 4) is essentially a metabolic pathway (mainly in liver and kidney) 
converting non-carbohydrate carbon substrates (e.g. i.e. lactate, pyruvate, glycerol, fatty 
acids, glucogenic amino acids) to glucose, via a chain of enzyme-catalyzed reactions. Since 
glycolysis (breakdown of glucose, Fig. 3) involves several irreversible steps, gluconeogenesis 
needs to bypass these regulatory steps to produce glucose. PEPCK (Phosphoenolpyruvate 
carboxykinase) converts oxaloacetate to phosphoenolpyruvate (PEP) and carbon dioxide at 
the expense of one GTP. This first step of gluconeogenesis is strictly regulated and crucial for 
glucose homeostasis.  
 
       
 
1.6.4  The pentose phosphate pathway  
The pentose phosphate pathway (PPP) is a metabolic pathway comprising an oxidative and a 
non-oxidative phase, where NADPH and 5-carbon sugars are generated, respectively (Fig. 5). 
Figure 4. Simplified schematic of 
gluconeogenesis. To prevent the blood 
glucose levels from dropping too low, 
“new glucose” can be synthesized from 
non-carbohydrate carbon substrates via 
gluconeogenesis. This pathway is strictly 
regulated and involves the bypass of 
irreversible regulatory steps in glycolysis. 
PEPCK performs the first, thus crucial 
for glucose homeostasis. 
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NADPH is important for reductive synthesis reactions within cells (e.g. fatty acid synthesis), 
and 5-carbon sugars are used in synthesis of nucleic acids and nucleotides. The first step in 
PPP is rate-limited by the enzyme glucose-6-phosphate dehydrogenase (G6PDH) that 
converts Glucose-6-phosphate (G6P) and NADP+ into 6-phosphoglucolactone and NADPH 
(Chettimada, 2016). G6PDH is generally considered to be regulated by the ratio 
NADPH:NADP+, thus as the ratio decrease the enzymatic activity is stimulated to generate 
more NADPH (Stanton, 2012).   
 
 
 
1.6.5 The mitochondrial turnover  
Mitochondrial transcription factor A (TFAM) is crucial for embryonic development (Larsson 
et al., 1998), key activator of mitochondrial transcription and required for the replication of 
the mitochondrial genome (Kang and Hamasaki, 2005).    
1.6.6 The metabolic sensor AMP-kinase  
AMP-activated protein kinase (AMPK) is a key sensor of cellular energy status consisting of 
a heterotrimeric protein complex, with one catalytic subunit (α) and two regulatory subunits 
(β and γ) (Hardie and Carling, 1997). AMPK belongs to the family of serine/threonine 
kinases and is allosterically regulated by competitive binding between ATP and AMP or 
ADP to the gamma subunit, thus sensing the cellular energy status by monitoring the 
AMP:ATP and/or ADP:ATP ratios (Hardie and Carling, 1997). Metabolic stress (e.g. 
hypoxia, glucose deprivation, muscle contraction) results in increased cellular ADP:ATP and 
AMP:ATP ratios that activate AMPK. Activated AMPK initiates energy-saving processes, 
influencing/regulating a range of physiological and metabolic processes e.g. lipid 
metabolism, glucose metabolism, protein synthesis (Hardie and Carling, 1997; Hardie 2007 
and 2011). Dysregulation of this AMPK has been implicated in different pathophysiological 
processes e.g. diabetes (Jeon, 2016).  
Figure 5. Simplified schematic of the Pentose 
Phosphate Pathway (PPP). The first step of 
PPP is rate-limited, controlled by Glucose-6-
phosphate dehydrogenase (G6PDH) generating 
6-phosphoglucolactone and NADPH from 
Glucose-6-phosphate and NADP+. NADPH is 
important for the reductive synthesis 
reactions in the cell. 5-carbon sugars, also 
generated via PPP, are used in the synthesis 
of nucleic acids and nucleotides. 
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1.6.7 The lipid synthesis and hydrolysis 
To generate free fatty acids, hormone sensitive lipase (HSL) hydrolyzes intracellular 
triglycerides in stored adipocytes, whereas lipoprotein lipase (LPL) hydrolyze extracellular 
triglycerides.  
HSL is regulated by the binding of various hormones (e.g. insulin, catecholamines) to 
specific receptors in the plasma membrane. Depending on the type of G-protein coupled to 
the receptor (Gs or Gi), adenylyl cyclase (AC) can be activated or inhibited. Activated AC 
increase the levels of cyclic AMP and activates PKA (protein kinase A, a cyclic AMP 
dependent protein kinase) that phosphorylate and activates HSL (Carey, 1998).  
Lipoprotein lipase (LPL) is a multifunctional protein that is mainly present in adipose, 
skeletal and heart muscle tissue. LPL is localized to the luminal side of blood capillaries and 
generates free fatty acids by hydrolyzing extracellular triglycerides (TG) carried in circulating 
lipoproteins (chylomicrons and very low density lipoproteins).  
 
 
 
Fatty acid metabolism (Fig. 6) is tightly regulated and very receptive to physiological needs. 
Also, the fatty acid synthesis and degradation are reciprocally regulated and cannot be active 
simultaneously (Lehninger et al., 2000).  
Acetyl-coenzyme A carboxylase beta (ACC2), catalyzes the formation of malonyl-CoA from 
acetyl-CoA and an irreversible step a rate-limiting step in biosynthesis of fatty acid. ACC2 is 
regulated by different hormones, resulting in the activation (by e.g. insulin) or inhibition (by 
e.g. glucagon, epinephrine) of enzyme activity (Lehninger et al., 2000).  
Malonyl-CoA is an important metabolite in fatty acid biosynthesis, where a decreased cellular 
level result in increased fatty acid oxidation (Folmes and Lopaschuk, 2007). It is thus, tightly 
regulated and Malonyl-CoA decarboxylase (MCD) catalyzes the conversion of malonyl-CoA 
into acetyl-CoA and CO2 (Foster, 2012).   
Figure 6. Simplified schematic of fatty acid 
metabolism. Fatty acid synthesis is dependent on 
the convention of Acetyl-CoA to Malonyl-CoA by 
ACC2. Next, FAS catalyze the convention of 
acetyl-CoA, malonyl-CoA and NADPH to 
palmitate, a precursor for long fatty acids. The 
intracellular level of Malonyl-CoA is tightly 
regulated, and MCD catalyze its formation back to 
Acetyl-CoA. 
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Fatty acid synthase (FAS) is an essential enzyme involved in fatty acid synthesis, catalyzing 
the complex conversion of acetyl-CoA, malonyl-CoA and NADPH to palmitate (Jayakumar, 
1995). Palmitate serve as a precursor for the synthesis of other long-chain fatty acids.  
 
1.7 ADAPTIVE CHANGES IN SMOOTH MUSCLE CONTRACTION 
Smooth muscle from different tissues exhibits a large span in contractile and signaling 
properties, and most likely also in characteristics of energy metabolism. An individual 
smooth muscle tissue can also adapt in vivo to altered functional demands and change to 
faster or slower contractile phenotypes with altered contractile protein expression (Arner et 
al., 2003). Changes in smooth muscle contractile activation/deactivation have also been 
reported for different patho/physiological conditions. For instance, altered RhoA-Rhokinase 
function has been described and several examples can be found, e.g. hypertension (Loirand 
and Pacaud, 2010), asthma (Chiba et al., 2010), and gastrointestinal dysfunction (Rattan et 
al., 2010). Changes in PKC have been found e.g. in bladder dysfunction (Hypolite and 
Malykhina, 2015) and vascular disorders (Ringvold and Kahlil, 2017). Altered Ca2+ 
sensitivity occurs in some conditions, e.g. in newborn bladders associated with altered  
MYPT expression (Ekman et al., 2005). Metabolic changes have been described but are 
rarely correlated with contractile or signaling properties. Although individual pathways can 
be affected in patho/physiological conditions and in some cases constitute a basis for 
pharmacological therapy (e.g. Fasudil®, a Rhokinase inhibitor used for treatment of 
vasospasm Feng et al., 2016; and other vascular conditions Shi and Wei, 2013), it would be 
important to relate any changes to contractile function and if possible obtain a more complete 
view on affected pathways. An identification of contractile, signaling and metabolic markers 
could be important for understanding pathological changes and for developing novel 
pharmacological therapies. 
 
1.8 URINARY BLADDER AND INCONTINENCE 
The physiological function of the urinary bladder is to store and expel urine. The smooth 
muscle (detrusor) in the wall of the bladder supports the three-dimensional structure of the 
organ and determines its wall tension. During the filling phase the detrusor muscle relaxes, 
allowing continuous expansion of the urinary bladder. Emptying of the urinary bladder 
requires a coordinated detrusor contraction and urethral relaxation (Andersson and Arner, 
2004).  
Impaired smooth muscle function is implicated in several pathophysiological conditions of 
the urinary bladder. Lower urinary tract symptoms (LUTS) is a major problem that increases 
markedly with age, affecting both male and females, especially in the elderly population 
(McDonnell and Brider, 2017) and can involve both overactivity and underactivity of the 
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detrusor muscle.  Effective treatment of LUTS is missing and better knowledge of smooth 
muscle regulation during physiology and pathophysiology is necessary.   
A common pathophysiological condition affecting the urinary bladder in humans as a part of 
LUTS is the overactive bladder (OAB) syndrome. OAB includes sudden and frequent urges 
to urinate, nocturia and incontinence. People living with OAB often experience 
embarrassment due to these factors, thus limit their social life or become isolated. Several 
treatments targeting receptors and signaling pathways have been introduced and proposed for 
OAB treatment although the success rate currently is low (Andersson, 2016). There are 
several conditions that can contribute to manifestation of OAB (Camões et al., 2015), e.g. 
ageing, ischemia and distension. An enlarged prostate can obstruct the urethra and induce 
hypertrophic growth of the urinary bladder, resulting in impaired bladder emptying and/or 
altered bladder storage of urine. The role of ageing and ischemia in OAB development is less 
understood although recent evidence suggest pelvic ischemia can be an important 
pathophysiological factor for detrusor overactivity and the overactive bladder syndrome 
(Andersson et al., 2017). 
The urinary bladder dysfunction in OAB is multifactorial and likely involves both neurogenic 
and myogenic factors. Changes in detrusor properties, receptor function and cell signaling 
have been reported but the exact causes are not completely understood. Many animal models 
have been developed to study different parts of the pathophysiological mechanisms affecting 
the detrusor muscle in OAB. Partial urinary bladder outlet obstruction is an animal model that 
induces smooth muscle hypertrophic growth and hyperplasia, and thus mimics some features 
of the OAB symptomology in human (e.g. Malmgren et al., 1987). Although extensive work 
on different signaling pathways in OAB have be presented, the Rho and PKC pathways in 
relation to receptor induced contractile responses are not fully understood.  
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2 AIM 
 
The general aim of this thesis project was to examine the cell signaling and regulation of 
smooth muscle in different smooth muscle tissues and under pathophysiological conditions.    
As pointed out in section 1.5, smooth muscle exhibits a large variability in its contractile and 
signaling properties, although clear distinction in muscle groups is not available.  
 The aim of Paper I was therefore to examine a range of smooth muscle tissues 
focusing on contractile, cell signaling and metabolic properties to examine if 
characteristics of fast and slow smooth muscle could be identified. 
Cell signaling in smooth muscle is affected in several disorders (section 1.7 and 1.8). 
 The aim of Paper II was to examine a mouse model for urinary bladder hypertrophy 
in response to urinary outlet obstruction (mimicking OAB in man) and examine 
possible changes in the two main Ca2+-sensitizing pathways, RhoA-Rhokinase and 
protein kinase C (PKC). 
In experiments for Paper II we made an observation that a prominent sustained contraction 
could be elicited by direct PKC activation in the obstructed hypertrophying urinary bladder 
smooth muscle. 
 The aim of Paper III was to examine the PKC-induced a contractile component in 
hypertrophying urinary bladder, with a special focus on the contribution of nonmuscle 
myosin. 
In Paper I we examined a range of signaling and metabolic components in different smooth 
muscles. The effects of metabolic pathways on cell signaling and contraction in fast and slow 
smooth muscles are largely unknown.     
 The aim of Paper IV is to examine the control of smooth muscle contraction by 
partial metabolic inhibition in a fast and slow smooth muscle type. 
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3 MATERIAL AND METHODS  
 
3.1 ANIMALS AND OPERATING PROCEDURES 
All studies in Paper I-IV were performed on adult C57/Bl6 mice (Taconic A/S, Denmark or 
B&K Universal AB, Sweden). Female mice were used in all studies; one exception is the 
qPCR in Paper I where male mice were used instead. The mice were housed at room 
temperature (12h light/12h dark cycle) and food and water were provided ad libitum.  
The surgical procedure, partial urinary outlet obstruction (Paper II, III), was performed on 
adult female mice (10-12 weeks old) anesthetized with isoflurane. The urethra was identified 
via a lower abdominal midline incision, and a 0.5 mm metal rod was placed alongside the 
urethra and a 4-0 ligature was tied to create a partial intravesical obstruction. The metal rod 
was then removed, and the abdomen was sutured in separate layers. Immediately after the 
surgery, the mice were given a local injection of local anesthetic Bupivacain (Marcain®) in 
the wound area. The animals were also given Buprenorfin (Temgesic®) twice daily for two 
days. Sham-operated animals were used as controls, and these were subjected to the same 
operating procedures, except for that the ligature was left untied around urethra instead. 
On daily basis, the general wellbeing of the operated animals was monitored, and no change 
in animal behavior or weight gain was noted. At 14-18 days after the surgical procedure, the 
animals were euthanized by cervical dislocation and the urinary bladder was removed 
weighed and used for in vitro experiments (Fig. 7). All husbandry and experiments were 
approved by the local animal ethics committee and conformed to the European Convention 
for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, 
Council of Europe No 123, Strasbourg 1985. 
 
 
Figure 7. Illustration of hypertrophic growth in the urinary bladder. A ligature was tied around 
urethra, creating a partial intravesical obstruction, leading to hypertrophic growth in the urinary 
bladder. About 2 weeks after the surgery the animals were euthanized, and the urinary bladder 
removed for in vitro force recording or Western blot analysis. 
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3.2 ISOLATION AND PREPARATION OF TISSUES 
In general, the animals were euthanized by cervical dislocation and smooth muscle tissues 
(aorta (Paper I, IV), mesenteric and femoral arteries (Paper I), ileum (Paper I), urinary 
bladder (Paper I-IV)) were quickly excised, transferred to ice-cold Krebs-Ringer solution 
(composition in mM: NaCl 123, KCl 4.7, KH2PO4 1.2, NaHCO3 20, MgCl2 1.2, glucose 5.5 
and CaCl2 2.5) and dissected from the surrounding connective tissue and fat. The urinary 
bladder for the studies in Paper II, III was denuded of urothelium and circular muscle strips 
were cut out from the midline equator of the bladder. The samples were used for in vitro 
force recordings (Section 3.3) for examination of pharmacological responses, nerve induced 
responses and determination of Ca2+ sensitivity and for determination of oxygen consumption 
(3.4). Samples were also chemically permeabilized /skinned (3.5) to examine Ca2+ sensitivity 
and fixed for immunohistochemistry (3.8). Tissues that were not used directly were rapidly 
frozen in liquid nitrogen in separate Eppendorf tubes and kept at -80oC until further analysis 
with Western blot (3.7) or qPCR (3.6). 
 
3.3 ISOMETRIC FORCE RECORDINGS ON INTACT MUSCLE PREPARATIONS  
3.3.1 Mounting for isometric force recording (Paper II, III, IV) 
For the in vitro force recordings in Papers II, III, IV circular muscle strips from the urinary 
bladder were cut out from the midline equator. In each end of the muscle strip (about 7 mm 
long and 0.3 mm thick) a 6-0 ligature was tied to enable mounting of the tissue in open organ 
baths (in 50 ml glass, Papers II and III or 5 ml Myograph System 610M, DMT, Paper IV). 
The aorta in Paper III (approximately 3-4 mm segment length length), was mounted on two 
thin metal rods in open organ bath (Myograph System 610M, DMT).  After mounting the 
muscle strips in the open organ baths, they were stretched to optimal length (passive tension 
to about 5 mN and 4 mN, for aorta and bladder, respectively, cf. Davis et al., 2012) and 
allowed to equilibrate for 45 min in a Krebs-Ringer solution (bicarbonate buffered 
physiological salt solution at 37oC, see composition in previous section) gassed with 
95%O2/5%CO2 (pH 7.4). For each sample 2-3 contractures induced by high K+ (80 mM) 
were induced to confirm reproducibility of contractions and determine an initial force 
response used for normalization of subsequent force responses. 
Several agonists and antagonists were applied in the in vitro experiments. Table 1 
summarizes the main substances, their action and in which paper they were used.  
3.3.2 Sensitivity to carbachol and αβ-methylene ATP (Paper II)  
The cholinergic and purinergic dose-force relationships were determined in detrusor muscle 
from obstructed urinary bladders (Paper II). First, muscle preparations were activated with 
increasing concentrations of carbachol (a cholinergic agonist, 100 nM to 100 μM). For each 
carbachol induced contraction the initial peak and sustained force after 5 min were 
determined.  Subsequently, after a control contraction with high K+ (80 mM), the muscles 
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were activated with αβ-methylene ATP (a P2X1 purinoceptor agonist (Bo and Burnstock, 
1995), 100 nM to 10 μM) for 1 min at each concentration and maximal response was 
recorded. The tissues were allowed to relax Krebs-Ringer solution for a 5 min wash period 
between each contraction. 
In separate series of experiments in Paper II, we used pharmacological blockers to analyze 
the relative contribution of Rho-kinase and PKC pathways in force development of 
hypertrophied urinary bladder in comparison with the sham-operated control bladders. To 
block Rho-kinase and the PKC pathway we used Y27632 (Ishizaki et al., 1996) and 
GF109203X (Coultrap et al., 1999) that inhibits these two enzymes respectively. After the 
equilibration period and the initial activation with high K+, the muscle was activated with 
carbachol (10 μM, 5 min). Thereafter, the preparations were incubated with Y27632 (10 μM) 
or GF109203X (1 μM) for 30 min followed by a second challenge with carbachol (10 μM, 5 
min) were the peak and sustained force was recorded. The effect of blockers on force was 
analyzed relative to the initial carbachol contraction (peak and sustained force values) in the 
absence of drugs.   
3.3.3 PKC-induced contractions, effects of blebbistatin (Paper III) 
When we performed the experiments for Paper II we observed that a significant PKC induced 
contractile response was present in the hypertrophic urinary bladder smooth muscle. This 
finding led to further experimental studies in Paper III.  The outline of the experiments is 
illustrated in Figs 3 and 4 of Paper III. We first examined the sensitivity to PDBu (an 
activator of PKC, Arcoleo and Weinstein, 1985) in control preparations and found that 1 µM 
PDBu gave a significant inhibition of active force and that 100 nM gave a small potentiation. 
The latter PDBu concentration was chosen for comparing control and hypertrophic bladders. 
We used muscarinic stimulation CCh (10 μM, 5 min) were the peak and sustained force 
values were recorded and activation with 100 nM PDBu (for 15 min). To determine if the 
PDBu induced contraction was dependent on ROCK, the tissue was incubated for 30 min 
with Y27632 (10 μM). In separate set of experiments in Paper III, we examined the PKC 
induced contraction in relation to nonmuscle myosin. The preparations were incubated 30 
min with blebbistatin (10 μM, an actomyosin inhibitor with higher affinity for nonmuscle 
myosin compared to smooth myosin, Limouze et al., 2004; Zhang et al., 2017) or DMSO 
control followed by activation with high K+ and CCh. The preparations were subsequently 
activated with PDBu (100 nM) and the force values after 15 min was determined.   
3.3.4 Effects of metabolic inhibition with rotenone (Paper IV) 
In Paper IV we studied the effects on smooth muscle contraction of metabolic inhibition in 
aorta and urinary bladder preparations. To introduce a partial metabolic inhibition we applied 
rotenone, a blocker of complex I in the respiratory chain of the mitochondria (Palmer et al., 
1968). The following standard protocol was applied for the in vitro force recordings: (1) the 
muscle preparations were first challenged with 2-3 high K+ control contractions (80 mM, 5 
min), (2) followed by 30 min incubation with rotenone (10 μM) or corresponding volume of 
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DMSO in controls. (3) After the incubation period, the preparations were again activated with 
high K+ followed by agonist stimulation; phenylephrine (10 μM, aorta, 5 min) or carbachol 
(10 μM, urinary bladder, 5 min) and subsequently with PDBu (1 μM, aorta, 20 min).  Each 
contraction was followed by a washout period were the preparations were allowed to relax in 
Krebs-Ringer solution for 5 min. Rotenone or DMSO for controls were replenished between 
each wash period. Maximal active force was evaluated relative the initial maximal K+ (80 
mM) peak response. 
To further examine different potential mechanisms underlying the reduced force in the 
rotenone treated tissue (Paper IV), we systematically targeted potential cellular mechanisms 
with blockers/activators and applied the standard protocol as described above. We focused on 
the following cellular targets:  ATP-dependent K+ channels: glibenclamide (10 µM, Zünkler 
et al., 1988); small conductance K+ channels (SK channels): NS8593 (10 µM, Strøbaek et al., 
2006); large conductance  K+ channels (BK channels):  penitrem (1 µM, Asano et al., 2012); 
AMP-kinase:  inhibitor dorsomorphin (10 µM, Pyla et al., 2014), activator AICAR (1 mM, 
Davis et al., 2012; Pyla et al., 2014). For each compound effects of respective solvent control 
were examined in parallel.  
To examine if the endothelial- and NO-induced relaxation was affected by rotenone treatment 
(Paper IV), aorta preparations was incubated with (10 µM) rotenone or DMSO control, as 
described above, and subsequently activated with a submaximal dose of phenylephrine (1 
µM) until a stable level of contraction was reached after about 20 min. Acetylcholine was 
then added (at the stable plateau of the phenylephrine contraction) cumulatively (10 nM, 100 
nM, 1 µM) every 2-4 min followed by the addition of SNP (sodium nitroprusside, a nitrous 
oxide donor activating cGMP-induced relaxation in smooth muscle, Levy, 2005) as a single 
dose (10 µM) or cumulatively (0.1 nM, 1 nM, 10 nM, 100 nM, 1 µM, 10 µM) every 1-2min. 
3.3.5 Direct nerve stimulation, (Paper II) 
Smooth muscle preparations of the control and hypertrophic urinary bladders were analyzed 
by direct nerve stimulation (Paper II). The preparations were obtained, dissected and 
mounted in open organ bath as described in the previous sections (3.1, 3.2 and 3.3.1). We 
used electric field stimulation of the samples applying 0.5 ms pulses at different frequencies 
(1, 5, 10, 15, 20, 25, 30, 40 and 50 Hz) during 5 s at supramaximal voltage. We applied 
scopolamine (1 µM) to block muscarinic receptors, αβ-methylene ATP (1 µM) to block 
purinergic (P2X1) receptors and Tetrodotoxin (TTX, 1 µM) to block all nerve-induced 
contractions (Na+-action potentials) and evaluated the contraction due to direct activation. We 
could thus examine the relative role of each neurotransmitter pathway in the nerve induced 
responses.  
3.3.6 Measurement of the Ca2+ sensitivity, (Paper II, IV) 
The extracellular calcium sensitivity (Paper II) of contraction was determined by incubating 
the muscle for 15 min in Ca2+ free N-Krebs solution containing 1 μM of αβ-methylene ATP 
and scopolamine. Then the bladder strip was subjected to high K+ (80 mM) depolarizing the 
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tissue. Every 5 min the extracellular Ca2+ concentration increased cumulatively (from 0 to 5 
mM) by adding CaCl2 directly into the bath solution. To determine the effect of Rho-kinase 
on the Ca2+ sensitivity the experiments was performed in the presence and absence of 
Y27632 (10 µM).  
For the rotenone treated smooth muscle strips (urinary bladder) in Paper IV, we also 
determined if the calcium sensitivity of the tissue was affected. The protocol was essentially 
as described above.  
 
3.4 MEASUREMENT OF O2 CONSUMPTION, PAPER IV 
The oxygen consumption (Paper IV) in relaxed muscle strips from the urinary bladder was 
determined using an oxygen electrode essentially as described by Arner et al. (1990). Since 
we were unable to control the CO2 in these experiments, the tissue preparations were allowed 
to equilibrate for 45 min in a MOPS solution gassed with air, composition in mM: NaCl 118, 
KCl 5, MgCl2 1.2, Na2HPO4 1.2, MOPS 24, glucose 10, CaCl2 1.6 (pH of 7.4 at 37oC). 
Control experiments were made verifying that the rotenone inhibition of force was similar in 
MOPS and Krebs-Ringer solution. The muscle strips were incubated for 30 min with 
rotenone (10 μM) or DMSO in control. Next the tissue was mounted with silk threads to a 
glass holder and stretched to optimal length, held in a 1.3 ml glass chamber that was coupled 
with an oxygen electrode (Clark electrode, MLT1120, ADInstruments Ltd, Oxford, UK). The 
glass chamber contained a magnetic stirrer and before each experiment started the Clark 
electrode in the glass chamber was calibrated using air and N2. For each preparation, during a 
10 min period, the decrease in oxygen content in the glass chamber was recorded. After each 
experiment the muscle strip was weighed, and the oxygen consumption was related tissue wet 
weight, thus expressed in µmol min-1 gram-1. 
 
3.5 CHEMICAL PERMEABILIZATION AND STUDIES OF SKINNED SMOOTH 
MUSCLE FIBERS, PAPER II 
We performed studies on chemically permeabilized (skinned) urinary bladders (Paper II). In 
these preparations the PKC and ROCK pathways and sarcoplasmic reticulum are removed, 
while the contractile machinery and MLCK/MLCP remain. The purpose was to determine if 
the increased Ca2+ sensitivity of the obstructed urinary bladders was due to altered sensitivity 
to Ca2+ of the contractile machinery.  
Preparations of the bladder smooth muscle were permeabilized with 1% Triton X-100 (a 
detergent) and examined according to Arner and Hellstrand (1985). Initially the preparations 
were incubated for 30-60 min in a low Ca2+ solution with high K+ (to mimic intracellular 
environment) containing sucrose to maintain osmolarity (in mM: EGTA 5, KCl 50, sucrose 
150 and TES buffer 30, pH 7.4). Then, the tissue was incubated for another 4 h in the same 
solution with the addition of 1% Triton X-100, to permeabilize the membranes. Finally, the 
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tissue was rinsed to remove Triton and transferred to a relaxing (low Ca2+, ATP containing 
solution, with glycerol to prevent freezing and improve permeabilization) solution (in mM: 
EGTA 4, MgCl2 10, ATP 7.5, DTE (dithioerythritol) 0.5, TES 30, pH 6.9 and 50 % glycerol 
and stored at -15°C until further analysis. 
The chemically permeabilized bladder preparation were mounted with aluminum clips at 
each end and attached between two tungsten wire hooks, one connected to an AME force 
transducer (SensoNor, Horten, Norway) and the other to a micrometer screw (for length 
adjustment). The tissue was and held horizontally in a small bath (200 µL) at constant stirring 
and containing solutions with the following composition (in mM): 30 TES buffer, 4 EGTA, 2 
Mg2+, 3.2 MgATP, 12 phosphocreatine, 150 KCl and 0.5 µM calmodulin and 0.5 mg/ml 
creatine kinase, adjusted to pH 6.9. Relaxation and contraction solutions was prepared by 
altering the free [Ca2+], determined by the ratio of CaEGTA/EGTA in the solution. The 
relaxation and contraction solutions had 10-9 M (pCa 9) and 10-4.3 M (pCa 4.3) of free Ca2+ 
concentrations respectively and intermediate Ca2+ concentration was achieved by mixing 
these two buffers. The active force at increasing free [Ca2+] was determined and expressed 
relative to the maximal force at 10-4.3 M of free [Ca2+]. 
 
3.6 REAL TIME QUANTITATIVE PCR, PAPER I 
Real time quantitative PCR (qPCR) was performed in Paper I to determine if key 
components in metabolic pathways differed between fast and slow smooth muscle types. The 
mRNA from different smooth muscle tissues (aorta, femoral artery, ileum and urinary 
bladder), were extracted with RNeasy Kit (Qiagen). The purity and concentrations of the 
mRNA was determined by measuring in a NanoDrop spectrophotometer at 260/280 nm and 
at 260/230 nm (acceptable values >1.9 and >2.0 respectively). The cDNA of the metabolic 
enzymes was generated with High Capacity Reverse Transcription Kit (Applied Biosystems) 
and analyzed in duplicates on 96-well plates with RT-qPCR (quantitative real time PCR) 
technique using Fast SYBR Green MasterMix and a real-time PCR from Applied 
Biosystems. All primers used are presented in Table 1 of Paper I. Hypoxanthine-guanine-
phosphoribosyl transferase (HPRT) was used as housekeeping gene. We used the relative 
standard curve method with pooled samples from all tissues as standard and normalized to 
HPRT (similar to delta-delta Ct method). All mRNA values in diagrams of Paper I are 
expressed relative to the standard normalized to HPRT.  
We also determined the mRNA expression of the inserted myosin heavy chain (SM-B) using 
regular PCR. In this case the primers result in products with different size depending on the 
presence (SM-B) or absence (SM-A) of the base pairs corresponding to the extra 7 amino 
acid insert in SM-B. The products were separated on agarose gels and the relative expression 
of SM-B (evaluated as larger product band/sum of both bands) was used as a marker for 
expression of fast smooth muscle myosin.   
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3.7 QUANTITATIVE WESTERN BLOT ANALYSIS, PAPER I, II & III 
In Paper I, II and III quantitative Western blot analysis was used to determine different cell 
signaling and contractile proteins in different smooth muscle tissues; Paper I: aorta, 
mesenteric artery, ileum and urinary bladder; Paper II and III: normal and hypertrophic 
urinary bladder.   
Isolated smooth muscle tissues were placed in a precooled (liquid nitrogen) mortar. The 
tissue was thoroughly pulverized and then dissolved in homogenizing buffer; 1 % SDS, 1 
mM Na3VO4 and 1 % PMSF (phenylmethylsulfonyl fluoride). Determination of the protein 
concentration was made using a protein assay from Bio-Rad (Richmond, CA). Then, samples 
were separated using SDS-PAGE, loading equal amount of protein from each sample, using a 
MiniGel system (Bio-Rad). Proteins from each gel were blotted onto nitrocellulose 
membranes and stained with a primary and a secondary antibody, subsequently visualized 
with enhanced chemiluminescence kit (ECL, Amersham Bioscience) and analyzed using 
Quantity One software from Bio-Rad. Eight different primary antibodies were used in the 
studies (Papers I, II): rabbit PKC (Santa Cruz Biotechnology Inc., California, USA), rabbit 
CPI17 (Upstate, Lake Placid, New York, USA), rabbit PP1β (Calbiochem, Darmstadt, 
Germany), mouse RhoA (Santa Cruz), rabbit RhoGDI (Santa Cruz), goat ROCK1 (Santa 
Cruz), goat ROCK2 (Santa Cruz), goat MYPT-1 (Santa Cruz). For Paper III: rabbit SMemb 
(nonmuscle myosin B, from Drs I. Morano and H. Haase, Berlin). In Western blot analysis 
the intensity of the ECL signal for each sample was normalized to the signal from the normal 
urinary bladder samples. 
 
3.8 IMMUNOHISTOCHEMISTRY, PAPER III 
Immunohistochemistry was performed in Paper III to visualize the localization of 
nonmuscle myosin and estimate if the expression is altered in obstructed relative to sham-
operated urinary bladders. Urinary bladders were fixed in 4% paraformaldehyde (PFA) and 
frozen sections were made. A pre-conjugated smooth muscle alpha actin antibody was used 
to visualize the smooth muscle layer in the tissue sections. Nonmuscle myosin was visualized 
by staining with a primary antibody SMemb and a fluorescent secondary antibody. Images 
were obtained with a confocal microscope (Zeiss LSM510) and analyzed with LSM Image 
Browser (Carl Zeiss AG, Oberkochen, Germany) and Adobe Photoshop (Adobe Systems 
Inc., San Jose, CA).  
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Table 1. Pharmacological substances (blockers and activators) used in the different papers. 
 
 
 
 
 
 
 
 
 
 
Compound  Cellular target/action Tissue  
(from mouse) 
Paper 
α,β-mATP α,β-methylene ATP.  Agonist and desensitizer of P2X1 
purinoceptors. A more stable analog of ATP.  
Urinary bladder II 
Acetylcholine 
(ACh) 
Acetylcholine binds to muscarinic receptor and induce 
endothelium-dependent relaxation of the smooth muscle. 
Aorta 
 
IV 
AICAR Activator of “AMP-activated protein kinase” (AMPK). Aorta 
Urinary bladder 
IV 
Blebbistatin Inhibitor of actomyosin with a weak affinity smooth and 
stronger for nonmuscle myosin II. 
Urinary bladder III 
 
Carbachol 
(CCh) 
Cholinergic agonist. Activates the acetylcholine receptors. Urinary bladder II, III, 
IV 
DMSO Dimethyl sulfoxide.  Anhydrous solvent used to dissolve 
pharmacological substances (blockers and activators).  
Aorta 
Urinary bladder 
II, III, 
IV 
Dorsomorphin   “Dorsomorphin dihydrochloride” also known as 
“Compound C”. Potent inhibitor of AMPK.  
Aorta 
Urinary bladder 
IV 
GF109203X A potent and selective competitive inhibitor of Protein 
Kinase C (PKC).   
Aorta 
Urinary bladder 
II, III 
Glibenclamide Blocker of ATP-sensitive K+ channels.   
 
Aorta 
Urinary bladder 
IV 
NS8593 Blocker of SK channels “small conductance Ca2+-activated 
K+ channels”.   
Aorta 
Urinary bladder 
IV 
PDBu Phorbol 12,13-dibutyrate. Activates protein kinase C (PKC). Aorta 
Urinary bladder 
II, III, 
IV 
Penitrem A Blocker of BK channels “large conductance Ca2+-activated 
K+ channels”. 
Aorta 
Urinary bladder 
IV 
Phenylephrine 
(Phe) 
Agonist of α1-adrenoceptors. Aorta 
Urinary bladder 
IV 
Rotenone Inhibitor of complex I in the electron transport chain of 
the mitochondria. 
Aorta 
Urinary bladder 
IV 
Scopolamine Scopolamine hydrobromide. Non-selective muscarinic 
antagonist. 
Urinary bladder II 
 
SNP Sodium nitroprusside. NO-donor that activates guanylyl 
cyclase (GC), and thus can induce relaxation of the smooth 
muscle independent of the endothelium. 
Aorta IV 
TTX Tetrodotoxin.  Blocks nerve transmission. Binds to the 
voltage-gated sodium channels thus inhibits action 
potentials in neurons.  
Urinary bladder II 
Y27632 Inhibitor of ROCK “Rho-associated protein kinase”. 
 
Urinary bladder II, III 
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4 RESULTS AND DISCUSSION 
 
4.1 SMOOTH MUSCLE CONTRACTILE KINETICS CORRELATES WITH SM-B 
EXPRESSION  
Smooth muscle is a heterogenic tissue with a large span in contractile, metabolic and 
regulatory properties (section 1.5). No clear characterization of “smooth muscle types” is 
however available today. Therefore, in the first study (Paper I), we focused on the 
complexity of smooth muscle characteristics aiming at developing a more comprehensive 
view of smooth muscle types.  
Since smooth muscle, like all muscles, converts metabolic energy to contractile function in a 
regulated process and exhibits a large span (about 5-7-fold difference) in contractile kinetics, 
it seems logical to divide the smooth muscle according to the contractile kinetics, similar to 
the division of skeletal muscle, i.e. fast (type II) and slow twitch (type I). In the skeletal 
muscle, several contractile and structural parameters and expression of regulatory, metabolic, 
cytoskeletal and contractile proteins differ between the muscle types (Schiaffino and 
Reggiani, 2011). In smooth muscle tissues also vary in the intracellular signaling (i.e. 
activation/deactivation). Also, although the smooth muscle is generally considered an 
economical tissue, a more detailed metabolic picture of this diverse tissue is missing. It could 
thus be argued that the a more complete characterization the smooth muscle could involve 
consideration of contractile, cell signaling and metabolic parameters.  
In Paper I we chose a set of smooth muscles from the mouse, exhibiting a large difference in 
contractile kinetics: the urinary bladder, intestinal muscle, muscular arteries and aorta.  Our 
starting point for the division was the maximal shortening velocity (Vmax). This parameter is 
considered to reflect the kinetics of the acto-myosin cross-bridge turnover, and to be rate-
limited by the rate of ADP release after completion of the power stroke (cf. Arner and 
Malmqvist, 1998; Löfgren et al., 2001;). The Vmax values have been determined in our 
laboratory for several of these smooth muscles and data can also be found in the literature. 
Variation in the values can be dependent of species, experimental temperature, mode of 
activation (skinned or intact muscle), and the method used. Approximate Vmax values at 20-22 
oC in muscle lengths per second (ML/s) were for aorta: Löfgren et al., 2001 (0.015 ML/s, 
guinea pig), Rhee et al., 2006 (0.07 ML/s, mouse); muscular artery: Davis and Davison, 2002 
(0.02 ML/s, mouse caudal artery, corrected for temperature); intestine: Risse et al., 2012, 
(0.09 ML/s, mouse ileum , corrected for temperature),  Löfgren et al., 2002 (0.11 ML/s, 
guinea pig), Malmqvist and Arner, 1991 (0.20 ML/s, taenia coli guinea pig); urinary bladder: 
Scott et al., 2008 (0.19 ML/s mouse). When reviewing the available data, a clear picture 
emerges, where the aorta belongs to a “slow” group whereas the urinary bladder would be 
“fast”. It is likely that intermediate groups exist (cf. Malmqvist and Arner, 1991), but in our 
study we chose to initially screen 4 smooth muscle tissues and measure several signaling and 
metabolic parameters. The analysis was mainly focused on the fast bladder and the slow 
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aorta, and we expect that our identification of the main characteristics of these two extremes 
can be used in the future to screen a larger number of smooth muscles possibly different 
species with fewer parameters, to directly answer the question if intermediate groups exist.    
 
Tissue Organ Type Vmax SM-B  
Aorta Large elastic 
artery 
Slow 0.015-0.07 0.07 
Femoral/ 
Mesenteric artery 
Muscular artery Slow 0.02 0.11 
Ileum Visceral Fast / 
Intermediate 
0.09-0.20 0.59 
Urinary bladder Visceral Fast 0.19 0.91 
 
The myosin isoform expression is one factor that determines the contractile kinetics of the 
smooth muscle, and the inserted myosin heavy chain (SM-B) has been reported to translocate 
actin at a higher velocity (Kelley et al., 1993) compared to the non-inserted variant (SM-A). It 
is clear that also the essential light chain isoform (LC17) composition correlates with Vmax 
(Malmqvist and Arner, 1991) and that nonmuscle myosin is expressed and can influence the 
kinetic in the slow aorta (Rhee et al., 2006). We used the relative expression of SM-B 
(determined with PCR) as a marker for contractile kinetics and we first determined the 
expression of the inserted myosin heavy chain (SM-B) in the selected tissues using PCR. As 
illustrated in Table 2 a strong correlation exists between SM-B expression and Vmax values 
(extracted from the literature above, cf. Arner et al., 2003) for the different smooth muscle 
tissues. Thus, in Paper I SM-B is used as a marker for kinetics of the contractile system and 
high expression relates to a fast contractile type. The urinary bladder represents a fast 
contractile type, the aorta and arteries slow smooth muscles and the intestine possibly an 
intermediary type.   
 
4.2 DIFFERENCE IN METABOLIC PATHWAYS BETWEEN FAST AND SLOW 
SMOOTH MUSCLE 
We displayed the metabolic and signaling parameters in relation to the SM-B expression (cf. 
Table 2, used in all Figures in Paper I, and in Figs 8 and 9 below). We applied qPCR (real 
time quantitative PCR) using primers from 15 different metabolic enzymes and factors 
(primers mainly from Sjögren et al., 2007, listed in Table 1 in Paper I) to address the aim if 
Table 2. Smooth muscle tissues exhibit a large span in contractile kinetics 
(shortening velocity, Vmax). Relative SM-B expression correlates with shortening 
velocity and is thus a marker for the contractile system. 
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the metabolic components were related to the contractile kinetics. We chose metabolic 
components for different pathways in the energy metabolism (section 1.6). We found that 
components of glucose uptake pathway were more expressed in the slow aorta smooth 
muscle. The insulin independent GLUT1 and hexokinase were markedly higher expressed in 
the slower compared to the faster tissues (panel A of Fig. 8 below and Fig. 3 in Paper I). Our 
measurements relate to the mRNA expression and if these values are correlated with high 
protein expression and activity the data would suggest that the slow muscles have a larger 
capacity for glucose uptake. Higher expression of GLUT1 has been correlated with higher 
glucose uptake (Kaiser et al., 1993) in smooth muscle and the hexokinase is the initial and 
rate limiting step in glucose uptake (Lehninger et al, 2000). Although the slow vascular 
smooth muscle would have a more economical mode of contraction with low ATP turnover 
(Arner and Hellstrand, 1981), these tissues are required to be contracted for longer periods 
during sustained tension maintenance in the vascular wall. It is likely that a continuous 
support of energy is physiologically important to enable long contractions, when cellular 
energy stores might be depleted. A consequence of an active insulin independent glucose 
uptake and efficient glucose metabolism might also be that the arterial muscles are more 
sensitive to high extracellular glucose levels, providing a potential contributing factor for 
vascular disease in diabetes/metabolic syndrome (Petrie et al., 2018). Interestingly the slow 
vascular tissues also had high expression of PEPCK (Phosphoenolpyruvate carboxykinase), 
which catalyzes the conversion of oxaloacetate to phosphoenolpyruvate, an initial step in 
gluconeogenesis (panel B of Fig. 8 below). Although the function of this pathway is unclear 
at present the expression of PEPCK appears to be a prominent marker for a slow smooth 
muscle. The expression of LDH (lactate dehydrogenase) was similar in the different tissues. 
However, it has previously been observed that the slow aorta expresses more of the H-form 
of LDH (less prone to produce lactate) compared to the faster urinary bladder smooth muscle 
(Malmqvist et al., 1991a). The faster bladder muscle can decrease the expression of the H-
form and changes towards a slower phenotype during hypertrophy (Malmqvist et al., 1991a; 
Sjuve et al., 1996), showing that LDH isoform expression is not simply correlated with the 
contractile kinetics, but might be associated with other metabolic demands. G6PDH 
(Glucose-6-phosphate dehydrogenase) is a key enzyme in the pentose phosphate pathway 
generating NADPH which is important for protection against oxidative stress. Deficiency in 
G6PDH expression is correlated with cardiovascular disease and decreased cellular defense 
against oxidative stress (Hecker et al., 2012). A negative correlation between G6PDH activity 
and expression of contractile proteins has been reported (Chettimada et al., 2016). Although 
speculative, the lower expression in the urinary bladder might reflect a higher sensitivity to 
oxidative stress and promote the maintenance of a contractile phenotype.  
AMP-activated protein kinase (AMPK) is a metabolic sensor activated in conditions of high 
AMP/ATP ratios (Hardie, 2011). The enzyme has several targets and in smooth muscle it has 
been reported to induce a relaxation of vascular smooth muscle via inhibition of PKC (Davis 
et al., 2012). In skeletal muscle it promotes glucose uptake and AMPK is a main target for the 
antidiabetic compound metformin (Zhou et al., 2001). We report a slightly higher expression 
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of AMPKα2 isoform in the faster smooth muscles, which does not correlate with the relaxant 
effect of AICAR, which is most prominent in the aorta.  However as reported in Paper IV of 
this study, AMPK might have a protective action under ischemic conditions and a higher 
expression can be important in this action in the urinary bladder (cf. Section 4.8). 
Major differences between the fast and slow smooth muscles were observed in the expression 
of enzymes involved in lipid synthesis (FAS: Fatty acid synthase, ACC2: Acetyl-coenzyme A 
carboxylase beta) and hydrolysis (HSL: hormone sensitive lipase, LPL: lipoprotein lipase). 
The expression patterns are shown in Fig. 5 of Paper I and exemplified in panel C of Fig. 8, 
below. These enzymes were significantly higher expressed in the slow smooth muscle, which 
suggests an enhanced lipid turnover. The higher FAS and ACC2 in slow muscle would 
promote fatty acid synthesis. Interestingly, ablated ACC2 in mice leads to a resistance to 
obesity-inducing diets with less weight gain and reduced fatty acid accumulation (Wakil and 
Abu-Elheiga, 2009). A detailed analysis of these lipid metabolism pathways was not the aim 
of Paper I and it is presently unclear how the differences in these enzymes are related to 
cellular metabolism in fast and slow smooth muscle. However, but these lipid metabolism 
enzymes are clearly strong markers for the smooth muscle phenotype. 
 
 
Figure 8. Expression of key metabolic components in smooth muscles with different kinetics. 
Aorta (diamond), muscular artery (triangle), ileum (square) to urinary bladder (circle). The expression 
of mRNA for the respective enzyme is related to the contractile kinetics evaluated by the relative 
expression of inserted myosin heavy chain. (SM-B). Figure modified from Figs 3-5 in Paper I.  
 
4.3 DIFFERENCE IN CELL SIGNALING PATHWAYS BETWEEN FAST AND 
SLOW SMOOTH MUSCLE 
In a second part of Paper II we used quantitative Western blot analysis to determine different 
cell signaling proteins from the main Ca2+ sensitizing pathways (RhoA, PKC, MLCP) 
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focusing on 8 different proteins. The main finding was that the slower muscles (aorta, 
muscular artery) had low expression of the phosphatase subunit MYPT1 (panel A of Fig. 9), 
higher expression of the ROCK1 isoform (panel C of Fig. 9) and higher expression of CPI17 
(panel B of Fig. 9, mainly in the aorta). The catalytic subunit (PPIβ) was not different 
between tissues, but the expression of the targeting subunit MYPT1 was clearly different with 
a lower expression in the slower smooth muscles (panel A of Fig. 9, below). It has been 
shown that low expression of MYPT1 is correlated with a lower phosphatase activity and a 
generally higher Ca2+ sensitivity (Ekman et al., 2005).  A low phosphatase activity has 
previously been reported for tonic compared to phasic smooth muscles (Gong et al., 1992). 
This seems to be coordinated with higher expression of components of both RhoA pathway 
(ROCK1) and the main target for PKC (CPI17). Expression of the latter protein is most likely 
related to increased PKC induced sensitization (Woodsome et al., 2001), and to the sustained 
and significant PDBu-induced contraction observed in the aorta (e.g. Fig. 1 panel A of Paper 
IV). The slow muscle thus also appears to have a higher capacity for Ca2+ sensitization via 
receptor activation and a slower relaxation.   
 
 
Figure 9. Expression of key cell signaling components in smooth muscles with different kinetics. 
Aorta (diamond), muscular artery (triangle), ileum (square) to urinary bladder (circle). The protein 
expression for the respective cell signaling component is related to the contractile kinetics evaluated 
by the relative expression of inserted myosin heavy chain. (SM-B). Figure modified from Figs 1-2 in 
Paper I.  
 
It should be stressed that our analysis in Paper I was focusing on identifying key markers for 
fast and slow smooth muscles, based on Western blot analysis and qPCR.  Although protein 
and mRNA expression most likely are associated with protein/enzyme activity, we cannot at 
present definitively show that our measurements reflect functional differences.  A logical next 
step for future studies would be to choose 2-3 metabolic enzymes that display a major 
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difference in mRNA and protein expression between fast and slow smooth muscle and 
measure the expression and activity of these enzymes in a broader range of smooth muscle 
tissues.    
 
Table 3. Main characteristics of fast and slow smooth muscle types  
 
 Properties of the 
smooth muscle 
“fast” smooth muscle 
  e.g. urinary bladder 
“slow” smooth muscle 
  e.g. aorta 
Co
nt
ra
ct
ile
 
Shortening kinetics ↑ high Vmax* ↓ ~5 times slower*  
Tension development ↑ high rate of tension 
development* 
↓ ~2 times slower* 
Myosin types ↑ 
↑ 
↓ 
high LC17a* 
high SMHC-B  
low nonmuscle myosin* 
↓ 
↓ 
↑ 
 
~16 times lower* 
~12 times lower  
higher nonmuscle myosin* 
ADP dependence ↓ low MgADP affinity* ↑ 
 
~36 times higher affinity* 
ATP dependence ↑ high MgATP affinity* ↓ ~4 times lower affinity* 
Phosphate dependence ↑ high Pi inhibition of force* ↓ ~2-4 times lower Pi inhibition* 
M
et
ab
ol
ic
 
Glucose uptake and 
glycolysis 
↓ 
 
↔ 
 
↓ 
↔ 
 
lower insulin independent 
GLUT1 
no difference in insulin 
dependent GLUT4  
low hexokinase  
PYRK no difference  
↑ 
 
↔ 
 
↑ 
↔ 
 
~3 times higher  
 
no difference 
 
~13 times higher  
no difference  
Lactate production ↔ 
↓ 
LDH no difference 
low LDH-H* 
↔ 
↑ 
no difference 
~1.4 times higher*  
NADPH synthesis ↔ G6DPH no difference ↔ no difference  
Gluconeogenesis ↓ low PEPCK ↑ 
 
~43 times higher  
Mitochondrial signalling ↔ TFAM no difference ↔ no difference 
Metabolic sensing ↔ 
↑ 
AMPK1 no difference 
high AMPK2  
↔ 
↓ 
no difference 
~5 times lower 
Lipid metabolism ↓ 
↓ 
low HSL 
low LPL 
↑ 
↑ 
~10 times higher 
~13 times higher 
Lipid synthesis ↓ 
↓ 
↔ 
low FAS 
low ACC2 
MCD no difference 
↑ 
↑ 
↔ 
~6 times higher 
~8 times higher 
no difference 
Ce
ll 
si
gn
al
in
g 
Dephosphorylation of 
myosin 
↑ 
 
↔ 
high expression of targeting 
subunit, MYPT1  
no difference catalytic subunit 
PP1β 
↓ 
 
↔ 
~6 times lower 
 
no difference 
Protein kinase C pathway ↓ 
↔ 
low CPI17 
PKCα no difference  
↑ 
↔ 
~3 times higher  
no difference 
Rho-Rhokinase pathway ↓ 
↔ 
low ROCK1 
no difference in ROCK2, RhoA 
and RhoGDI 
↑ 
↔ 
~7 times higher  
no difference 
* Data obtained from the literature. Table modified from Table 3 in Paper I. 
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4.4 MAIN PROPERTIES OF FAST AND SLOW SMOOTH MUSCLE 
In a summarizing Table 3 modified from Table 3 in Paper I we attempted to make a more 
systematic characterization of slow and fast smooth muscle types according to the main 
parameters (contractile, metabolic, and cell signaling). In general, a slow smooth muscle, 
e.g. found in large arteries, have slow cross-bridge turnover with low shortening velocity and 
high tension economy which is correlated with expression of proteins associated with slow 
acto-myosin turnover (low SM-B, high LC17b and high expression of nonmuscle myosin). It 
has slow kinetics in its deactivation (low phosphatase) and high expression of components on 
Ca2+ sensitizing pathways and would thus be able to modulate its contraction via receptor 
activation. Its energy consumption is generally lower than in faster smooth muscles, but its 
ability to take up glucose as well as lipid turnover is high, possibly related to the requirement 
of sustained energy supply and possibly also related to an increased sensitivity to 
extracellular glucose levels.  
 
4.5 PARTIAL URINARY OUTLET OBSTRUCTION INDUCES HYPERTROPHIC 
GROWTH  
Paper I, discussed above, identified key properties of fast and slow smooth muscle. It can 
also be asked if an individual smooth muscle can change its properties.  In different 
physiological situations and in pathophysiology, smooth muscle can undergo significant 
adaptation in structure and function. With regard to contractile function, changes in the cross-
bridge kinetics towards faster and slower phenotypes have been described in different animal 
models, e.g. during hypertrophic growth in the urinary bladder (Sjuve et al., 1996; Scott et al., 
2008), in asthma in trachea, after thyroxin treatment in intestine (Löfgren et al., 2002). 
Adaptation and changes in cell signaling is of significant interest since information on these 
cellular mechanisms can provide a basis for pharmacological therapy of smooth muscle 
pathologies. As mentioned in the Introduction (Section 1.8) alterations in urinary bladder 
function with the over active bladder syndrome and incontinence are common and introduce 
significant burden to the affected persons and to our society. Research and therapeutic 
initiatives are extensive but yet not fully successful (Andersson, 2016). In Paper II we 
addressed adaptation in cell signaling properties including both PKC and RhoA signaling 
pathways in a mouse model for urinary bladder hypertrophy/overactivity, resembling changes 
in urinary outflow occurring e.g. after prostatic enlargement. We used a mouse model 
(Pandita et al., 2000; Sjuve et al., 1995; Scott et al., 2008) to induce hypertrophic growth of 
the urinary bladder by ligating the urethra to induce a partial urinary outlet obstruction that 
gave a significant increase of urinary bladder weight. The obstructed and sham-operated 
animals had no difference in animal weight gain. There was no change in general animal 
behavior or animal wellbeing. A normal adult mouse bladder (sham operated), weighed about 
20 mg and the partially outflow obstructed bladders increased in weight more than 3 times to 
about 65 mg in about 2 weeks. The increase in urinary bladder weight was associated with 
changes in contractile protein (actin and myosin) and with a relative increase in cytoskeletal 
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proteins (intermediate proteins desmin/vimentin) similar to that described previous for mouse 
and rat (Malmqvist et al., 1991b; Scott et al., 2008). 
 
4.6 INCREASED SENSITIVITY TO CHOLINERGIC STIMULATION IN 
HYPERTROPHIC BLADDER 
A first step in Paper II was to examine the physiological regulation of the control and the 
hypertrophic bladder detrusor via direct activation if the intramural nerves. The samples were 
stimulated using electrical field stimulation at different frequencies. Increased frequency gave 
increased active force (see Fig. 10 below, and Fig. 1 in Paper II). By adding scopolamine (a 
muscarinic receptor blocker) we could identify the relative contribution of the cholinergic 
nerve component. In controls, scopolamine reduced the nerve induced responses by about 45 
% whereas the hypertrophic bladders were more inhibited (by about 70%), suggesting a 
larger relative contribution from the cholinergic pathway in the hypertrophic bladders.   
 
 
 
Further addition of α,β-methylene ATP (which desensitizes the P2X1 purinoceptors) reduced 
the nerve mediated responses of controls significantly, but had only minor effects on the 
obstructed bladders, suggesting a downregulation of the ATP-dependent contractile 
activation. Addition of TTX (a nerve blocker) reduced the contractile responses further by 
about the same amount in both tissues, reflecting a similar and marginal contribution from 
Figure 10. Electric field stimulation. Force response of control (A) and hypertrophic (B) 
urinary bladder preparations stimulated at different frequencies after application of blockers of 
nerve transmission to identify the muscarinic and the purinergic components in the responses; 
control (filled circles), 1μM scopolamine (white circles), 1μM αβ-mATP (filled squares), 1μM 
TTX (white squares). Figure modified from Fig. 1 in Paper II. 
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non-cholinergic and non-purinergic pathways. The remaining part of the responses to 
electrical field stimulation was increased in the hypertrophic muscles, reflecting an increased 
sensitivity to direct electrical stimulation if the bladder muscle. These results thus suggest that 
the hypertrophic urinary bladder downregulate the purinergic nerve component, upregulate 
the cholinergic nerve component and increase the sensitivity to direct electrical stimulation. 
Since the nerve induced responses suggested changes in reactivity of the hypertrophic 
muscle, we examined the pharmacomechanical and electromechanical coupling, i.e. after 
activation with direct depolarization (KCl) or agonists (the muscarinic agonist carbachol and 
the P2X1 receptor agonist α,β-methylene ATP) in the normal and hypertrophied urinary 
bladders. Contraction induced by high K+ is due to the depolarization and opening of voltage-
gated Ca2+ channels, increasing the intracellular [Ca2+] and triggering contraction by 
activating the MLCK. Carbachol is a cholinergic agonist, binding to a G-protein coupled 
receptor in the membrane that triggers a signaling cascade/network of enzymes activating the 
contractile filaments. The α,β-methylene ATP is considered to activate depolarization of the 
membrane via the P2X1 receptor opening a cation channel (Surprenant et al., 1995). The in 
vitro application of α,β-methylene ATP did not reveal a difference in the sensitivity between 
control and hypertrophic bladders (Panel A of Fig. 2 in Paper II), suggesting that the 
alteration in the purinergic nerve component resides in the nerve or nerve terminal rather than 
on the post synaptic receptor or cellular signaling.  
 
 
 
 
 
 
 
We observed an increased sensitivity to carbachol response in the phasic (peak) part of 
contraction (Panel B of Fig. 2 in Paper II) for the hypertrophied smooth muscle, whereas the 
Figure 11. Contractile response to carbachol stimulation. Original recordings in: control 
(Panel A) and hypertrophied (Panel B) bladder strips activated with 10 μM carbachol. Note 
the pronounced sustained contractile component in the hypertrophied smooth muscle. Panel 
C: Force responses of control (open circles) and hypertrophied (filled circles) urinary bladder 
preparations, activated with the muscarinic agonist carbachol. Figure modified from Fig. 2 in 
Paper II.  
  31 
tonic (plateau) part of carbachol contractile response gave about 1.5 times stronger (higher) 
maximal response at unaltered sensitivity to the agonist (Panel C of Fig. 11; Panel C of Fig. 
2 in Paper II). These findings are consistent with the result from the direct nerve stimulation.  
We examined if the enhanced cholinergic responses of the hypertrophic muscle could be due 
to an increase in the Ca2+ sensitizing pathways. Inhibition of the Rho kinase pathway (with 
Y27632) inhibited the plateau more than the peak in the control bladders, suggesting that the 
Rho kinase pathway is more active during the sustained phase of contraction in the urinary 
bladder. The effect of Y27632 on the hypertrophic bladders was similar, except for a slightly 
lower sensitivity of the plateau response. Inhibition of PKC (with GF109203x) inhibited 
force less than inhibition of the Rho pathway and no major differences could be observed 
between control and hypertrophic bladders (Fig. 3 of Paper II). We confirmed that Y27632 
and GF109203x also inhibited the more transient nerve induced contractions, to a similar 
extent in controls and hypertrophic preparations. These results thus suggest that the Rho 
pathway is recruited to a larger extent than PKC in bladder cholinergic activation. Changes in 
RhoA ad PKC are however not primarily responsively for the altered responses to in 
cholinergic stimulation (i.e. in pharmacomechanical coupling) in the hypertrophic urinary 
bladders. Interestingly, we found an increased sensitivity to [Ca2+] in high K+ depolarized (i.e. 
electromechanical coupling) tissues for the hypertrophied urinary bladders that was abolished 
with Y27632. This suggests that direct influx of Ca2+ seems to activate the Rho pathway as 
suggested by Ratz et al. (2005) or that a constituently active Rho signaling is present and 
becomes important during Ca2+ influx and becomes masked by cholinergic stimulation.  
Western blot analyses shoved that hypertrophic growth upregulates the RhoA and PKC 
signaling pathways whereas the MYPT-1 and PP1β were lowered (Fig. 5 in Paper II and 
Fig. 12, below). Interestingly, although the urinary bladder is a fast smooth muscle (as 
discussed in Paper I) these characteristics correlates better with a slow smooth muscle type, 
thus indicating that the hypertrophying urinary bladder undergo a transition from a fast to a 
slow smooth muscle type, consistent with mechanical data (Scott et al., 2008). We could 
however not correlate a decreased phosphatase activity to an increased Ca2+ sensitivity of the 
skinned muscle preparations (Panel C of Fig. 4 in Paper II), which might suggest that some 
additional factor is altered during skinning or that a change in phosphatase activity is linked 
to an increased Rho-kinase pathway as suggested by the Ca2+ sensitivity measurements in 
depolarized tissue.  
In conclusion, hypertrophic growth of the urinary bladder increases the sensitivity to 
muscarinic receptor stimulation, upregulation of components in Rho-kinase and PKC. 
However, these pathways are not activated to a larger extent after receptor activation in the 
hypertrophic muscle. Nevertheless, the Rho Kinase pathway is upregulated and contributes to 
Ca2+ sensitization after depolarization in hypertrophic bladders. Based on these results, one 
can speculate that Rho-kinase inhibition (i.e. Fausodil®) can be a potential therapeutic avenue 
in treating OAB, reducing the pathological phasic activity (electromechanical coupling) and 
leaving the receptor mediated (pharmacomechanical coupling) part of contraction less 
affected.  
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4.7 PKC INDUCED CONTRACTION IS ABOLISHED BY BLEBBISTATIN 
When performing the experiments for Paper II, we made an interesting observation which 
initiated further studies in Paper III. We found that a prominent contraction could be elicited 
by direct activation of protein kinase C (PKC) with PDBu (Phorbol 12,13-dibutyrate) in 
hypertrophied urinary bladder (illustrated in Fig. 13, and Fig. 3 and 4 in Paper II). As seen in 
Fig. 13 carbachol induced a transient contraction in a control bladder (upper trace) and a 
more sustained contraction in the hypertrophic bladder (lower trace), as previously also 
shown in Paper II. The control bladder did not respond to direct PKC activation by PDBu 
whereas the hypertrophied bladders developed a prominent sustained contraction (lower trace 
in Fig. 13). 
Smooth muscle tissue can express nonmuscle myosin in addition to smooth muscle myosin 
(Morano et al., 2000; Löfgren et al., 2003;  Rhee et al., 2006). Nonmuscle myosin heavy 
chain is expressed from separate genes (nonmuscle myosin A and B, MYH9, MYH10) 
relative to smooth muscle myosin and can form filaments and generate contraction with slow 
kinetics (Walklate, 2016). In the urinary bladder, nonmuscle myosin is expressed during fetal 
life and downregulated early after birth, thus not expressed normally in adult bladder 
(Löfgren et al., 2003). We examined the role of nonmuscle myosin and protein kinase C in 
regulation of the PDBu (PKC) induced contraction in the hypertrophic bladders, addressing 
the possibility that the hypertrophic growth caused development of a separated contractile 
component with unique activation. Nonmuscle myosin is an interesting candidate since it has 
been found to be upregulated in the serosa of hypertrophic urinary bladders from the rabbit 
(Sartore et al., 1999) and in cells of the interstitium of hypertrophied rat bladders (Sjuve et al., 
2001). This contractile component thus seems to be structurally separate from the smooth 
muscle.  
Figure 12. Expression of cell 
signaling components. Protein 
content (Western blot) in 
hypertrophied bladder tissue, 
relative to the expression in sham 
operated control bladders (line at 1). 
Figure modified from Fig. 5 in 
Paper II. 
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Immunohistochemistry (Fig. 1 of Paper III), showed a thicker smooth muscle (smooth 
muscle alpha actin positive) layer in the wall of the hypertrophied detrusor muscle. The 
nonmuscle myosin component (stained with SMemb, i.e. nonmuscle myosin B) could be 
sparsely observed in the wall of the control bladder, but increased markedly in the 
hypertrophic wall, both in the muscle layer and as a separate component in the serosa. It has 
been observed that PDBu (PKC activation) can induce a contraction in newborn urinary 
bladders expressing nonmuscle myosin, suggesting that PKC can activate this contractile 
component (Lamounier-Zepter et al., 2003). We found in Paper II that the PKC activated 
contractile component is not recruited during normal muscarinic membrane receptor 
activation, since these contractions in the hypertrophic muscle were not more sensitive to 
GF109203x (the PKC inhibitor) compared to the responses of the control. This is in contrast 
to the pronounced contraction elicited by direct PKC activation vid PDBu in the hypertrophic 
muscle (Fig. 13 above and Fig. 3 and 4 in Paper III). We show that the PDBu induced 
responses are not affected by Y27632, and therefore do not include activation of the 
Rhokinase pathway. Currently we do not know which cellular signaling pathway or receptors 
that can activate this separate PKC dependent contractile component in the hypertrophic 
muscles.  
To determine if nonmuscle myosin could be linked to the contractile response induced by 
PDBu we used blebbistatin, which is an inhibitor of actomyosin interaction. Blebbistatin 
targets nonmuscle myosin but has less effect on smooth muscle myosin (Limouze et al., 
2004; Zhang et al., 2017). The specificity of blebbistatin has been discussed; the first study 
Figure 13. Original force 
recordings. From control (upper 
trace) and hypertrophied (lower 
trace) mouse urinary bladders, 
first activated with carbachol 
(CCh) and thereafter with PDBu. 
Note the substantial force 
development after PDBu (PKC) 
activation in hypertrophied 
urinary bladder, which is not 
observed in control bladders. 
Figure modified from Fig. 3 in 
Paper III. 
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(Limouze et al., 2004) reported a very low inhibitory effect on smooth muscle actomyosin, 
whereas a subsequent report suggested that it was equally potent on smooth muscle (Eddinger 
et al., 2007). A more recent report comparing blebbistatin effects on smooth and nonmuscle 
myosins, show however a clear selectivity toward nonmuscle myosin over smooth (Zhang et 
al., 2017), which is consistent with blebbistatin effects in organized smooth muscle 
containing nonmuscle myosin (Rhee et al., 2006; Ekman et al., 2005). We find that 
blebbistatin partially inhibits the high K+ and carbachol induced contractions (Fig. 4 and 5 
Paper III) consistent with a small inhibition of smooth muscle myosin. However, the PDBu 
induced contractions in the hypertrophied bladder muscle were inhibited by more than 85% 
by blebbistatin (Fig. 5 in Paper III and Fig. 14 below).   
 
 
 
The main finding of Paper III is thus that hypertrophy of the urinary bladder in response to 
urinary outflow obstruction can lead to development of a structurally distinct wall component 
expressing nonmuscle myosin and activated by PKC. The physiological/pathophysiological 
mechanisms regulating this contractile component and if it can occur in the human bladder 
are unknown at present. Development of this structure might constitute a factor modulating 
the wall stiffness in bladder during hypertrophic growth.  
 
4.8 ROTENONE REDUCES O2 CONSUMPTION AND FORCE DEVELOPMENT 
The aim of Paper IV was to examine the metabolic aspect of force development, based on 
the idea that the contractile process in smooth muscle would be dependent on the energy 
supply with a difference between fast and slow smooth muscle types, described in Paper I. 
We address this question by introducing a partial block of the respiratory chain (at complex I) 
in the mitochondria using rotenone (Swärd et al., 2002). As a first step, we verified that 
blocking complex I with rotenone affects the oxygen consumption of the tissue. In the relaxed 
smooth muscle (urinary bladder) rotenone inhibited the oxygen consumption by about 50%, 
giving a significant metabolic inhibition (right panel in Fig. 15).  
Figure 14. Contractile response to PDBu in 
hypertrophied urinary bladder smooth 
muscle. Direct activation of PKC with 100nM 
PDBu, in Krebs-Ringer solution: open bars 
(control), hatched bars (10 μM Y27632), 
crosshatched bars (10 μM blebbistatin, 10 μM 
Y27632). Figure modified from Fig. 5 in 
Paper III. 
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Figure 15. Oxygen consumption in relaxed smooth muscle. Left panel: Apparatus that holds 
muscle preparation in a closed glass chamber (37oC) equipped with a Clark electrode that was used to 
measure oxygen consumption during 10 min. Right panel: Oxygen consumption in relaxed smooth 
muscle from the urinary bladder; in control (DMSO) white bar and after inhibition with rotenone, grey 
bar. Figure based on data in Paper IV. 
 
Active force of the smooth muscle was also significantly reduced by rotenone. Interestingly, 
the agonist induced active force in the rotenone treated tissue, was more affected in the fast 
(urinary bladder) compared to that of the slow (aorta) smooth muscle type, inhibited by about 
50% and 30% respectively. The ATP turnover of the aorta is significantly lower than in fast 
muscle (Arner and Hellstrand, 1981) and it might thus be less affected by low energy supply. 
The low sensitivity to rotenone of the aorta is also consistent with the results from Paper I, 
where we observed that the aorta has a high expression of components in glucose uptake and 
glycolysis compared to the fast smooth muscle. It is thus possible that the aorta muscle better 
can support ATP generation via glycolysis and be metabolically more adapted and better 
prepared for an ischemic challenge. In this study we measured active force and it should be 
noted that other contractile parameters, mainly shortening velocity can be affected by 
ischemia/rotenone in a different way compared to force. It is expected that the shortening 
velocity slow aorta would be more sensitive to increased ADP levels (Löfgren et al., 2001). 
Next, we tried to find a potential mechanism explaining the reduced force development in the 
rotenone treated smooth muscle tissue. We systematically examined potential cellular 
targets/pathways depicted in Fig. 16 (below) using different pharmacological compounds 
targeting membrane channels (ATP activated and small and large conductance K+ channels) 
and the metabolic sensor AMPkinase. We hypothesized that low ATP, induced by rotenone 
inhibition will lower ATP levels and increase ADP and AMP. A low ATP can activate KATP 
channels (Zünkler et al., 1988), hyperpolarize the membrane and lead to relaxation. Also, 
impaired Ca2+ removal via reduced activity of the sarcoplasmic reticulum pump (SERCA) 
can lead to Ca2+ activation of SK and BK KCa channels (Herrera and Nelson, 2002). If any 
such mechanism would apply, blocking of these K+ channels should be able to reverse the 
rotenone effects on force. We report that neither of the applied channel blockers had this 
 36 
effect (Fig. 2, Paper IV), excluding a major role of K+ channel opening in the reduced force 
in metabolic inhibition.  
 
 
Figure 16. Potential cellular mechanisms affected by rotenone treatment. Simplified schematic of 
cellular mechanisms potentially underlying the reduced force in the rotenone treated tissue and the 
pharmacological compound used in Paper IV to target these mechanisms. Rotenone reduces oxygen 
consumption and ATP levels via effects on the mitochondria. Lowered ATP will potentially open 
KATP channels and affect Ca2+ removal with activation of KCa channels. Altered high energy phosphate 
levels will also affect the contractile system and activate AMPK. 
 
The AMP-dependent kinase (AMPK) is a metabolic sensor activated by a change in 
metabolic status (Hardie, 2011). We have previously shown that activation of AMPK with 
AICAR leads to an inhibition of active force via an inhibition of protein kinase C and of the 
endothelial induced relaxation (Davis et al., 2012). It is possible that this mechanism is 
partially involved in the reduced force during rotenone treatment and in the impaired NO-
mediated relaxation (Fig. 5, Paper IV). We however made the unexpected finding that 
inhibition of AMPK with dorsomorphin (an AMPK inhibitor, Pyla et al., 2014) dramatically 
potentiated the rotenone inhibitory effect (Fig. 4, Paper IV, and Fig. 17 below). These results 
suggest that AMPK in smooth muscle (primarily the fast urinary bladder) has a protective 
action reducing the force inhibition during ischemia. The detailed mechanism remains to be 
explored, but in view of the effects of AMPK on glucose uptake (Musi and Goodyear, 2003; 
Nagata and Hirada, 2010) we suggest that AMPK is activated by the change in energy status, 
stimulating glucose uptake and promoting ATP generation via glycolytic pathways.  
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Figure 17. Relative inhibition in the presence of rotenone (filled bars) or with DMSO control (open 
bars) in the presence of AICAR (AMPKinase activator, diagonally hatched), or Dorsomorphin (Dorso, 
AMPKinase inhibitor, horizontally hatched) after activation with depolarization (KCl) or muscarinic 
agonist (carbachol, CCh) in the urinary bladdder. Figure based on data in Paper IV. 
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5 CONCLUSIONS 
Paper I; A slow smooth muscle (versus a fast smooth muscle):  
 found in large arteries  
 slow cross-bridge turnover with low shortening velocity and high tension economy  
 contractile proteins associated with slow actomyosin turnover 
 slow kinetics in its deactivation (low phosphatase)  
 high expression of components in Ca2+ sensitizing pathways and would thus be able 
to modulate its contraction via receptor activation  
 energy consumption that is generally low 
 ability to take up glucose, as well as lipid turnover is high, possibly related to the 
requirement of sustained energy supply and possibly also related to an increased 
sensitivity to extracellular glucose levels  
Paper II; Hypertrophic growth induces changes in the urinary bladder: 
 increased cholinergic responses, primarily due to post receptor changes 
 lowered purinergic responses, due to alteration in nerve function 
 increased Rho dependent Ca2+ sensitivity that correlated with higher RhoGDI and 
RhoA, and lower phosphatase (MYPT1) 
 alterations correlates more with a slow smooth muscle, rather than a fast smooth 
muscle  
Paper III; Hypertrophic urinary bladder can develop a nonmuscle myosin contractile 
component: 
 mainly localized in the serosa 
 activated by protein kinase C  
 not a major part of the normal muscarinic contraction, but may contribute to wall 
stiffness and be activated by other (unknown) upstream pathways 
Paper IV; Partial metabolic inhibition of mitochondrial complex I with rotenone: 
 reduces the oxygen consumption to about 50%, thus induces a significant metabolic 
inhibition 
 inhibits force development induced by depolarizing (high K+) and agonist induced 
contraction 
 force development in fast smooth muscle (urinary bladder) is more sensitive to 
metabolic inhibition compared to the slow smooth muscle (aorta) 
 AMPkinase has a significant protective action on the smooth muscle subjected to 
partial metabolic block 
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6 SVENSK SAMMANFATTNING 
 
Glatt muskulatur är den typ av muskelvävnad som är icke viljestyrd och finns representerad i 
många olika organ och organsystem i kroppen, bland annat i blodkärl, urinblåsa, tarmarna, 
livmoder etc. Den är involverad i olika viktiga processer i kroppen såsom reglering av 
blodtrycket, tömning av urinblåsan, tarmarnas rörelse och livmoderns sammandragningar i 
samband med förlossning. Eftersom glatt muskulatur finns uttryckt på så många olika platser 
i kroppen är det inte förvånande att många olika sjukdomar och sjukdomstillstånd kan vara 
relaterade till förändringar i den glatt muskulaturen. Som exempel kan nämnas inkontinens 
vid förträngningar i urinvägarna, astma, och kärlförändringar vid diabetes. 
Vi vet idag förhållandevis mycket om hur hjärt- och skelettmuskulatur fungerar och styrs, 
medan den glatta muskulaturens egenskaper är väsentligt mindre utforskade och klarlagda 
Studierna i denna avhandling innefattar försöksmodeller baserade på glatt muskelvävnad från 
försöksdjur (möss). I ett första arbete (Arbete I) visade vi att det finns olika typer av glatt 
muskulatur: snabba i tarm och urinvägar och långsamma i de stora kärlen. Dessa olika glatta 
muskeltyper är speciellt anpassade till sina unika funktioner i kroppen, tex upprätthålla 
blodtryck under låg energiomsättning i de stora kärlen eller dra samman urinblåsan för att 
tömma den. Snabba och långsamma glatta muskeltyper skiljer sig i kontraktila egenskaper, 
cellsignalering och metabolism. Vid olika sjukdomar och sjukliga tillstånd uppvisar glatt 
muskulatur en imponerande förmåga att anpassa sina egenskaper. Denna adaptationsförmåga 
studerades i det andra och tredje arbetet (Arbete II och III) i denna avhandling där vi visar 
att hypertrofisk tillväxt, liknande den som kan ske i urinblåsan vid t.ex. prostataförstoring, 
kan leda till förändrad cellsignalering med en ökad känslighet för kalcium som var medierad 
av en speciellt signalväg (Rho). Vi fann även att hypertrofisk tillväxt ledde till att det 
nervmedierade svaret förändrades, med en ökad känslighet för transmittorn acetylcholin vid 
direkt nervstimulering. Hypertrofisk tillväxt av urinblåsan kan leda till betydande uttryck av 
en speciell form av kontraktilt protein (non-muscle myosin, NMM), vilken är besläktat med 
de proteiner som utför kontraktionen i glatt muskulatur. Vanligtvis finns inte NMM i 
urinblåsa. Vi visar att hypertrofisk tillväxt av urinblåsan kan leda till utvecklandet av en unik 
kontraktil komponent, som kan aktiveras direkt via en unik signalväg (protein kinase C) och 
är beroende av NMM. Denna kontraktila komponent aktiveras inte vid normal kontraktion av 
urinblåsan, utan styrs av en separat (fortfarande okänd) mekanism. I ett sista arbete (Arbete 
IV) studerades hur kontraktionen i glatt muskulatur påverkas av en metabol blockering med 
rotenone. Rotenon ingriper i cellernas energiomsättning och hämmar syreförbrukning i 
mitokondrierna. AMPK är ett protein som känner av hur mycket energi som finns tillgängligt 
i cellen. Vi visar att metabol blockering minskar kraften i glatt muskulatur och den snabba 
muskeltypen är mycket mer känslig, jämfört med den långsamma glatta muskulaturen. 
AMPK kan delvis förhindra kraftminskningen vid metabol blockering med rotenone, och har 
sannolikt en skyddsfunktion vid energibrist och dålig blodförsörjning.  
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